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Abstract         
Introduction: Recombinant human growth hormone (rhGH) has been extensively used by 
healthy young males and athletes in the attempt to improve body mass and sports 
performance. The expression of GH receptors (GHR) has been reported previously by dual 
fluorochrome flow cytometry on human peripheral blood lymphocytes (PBL). In the human, 
rat, and dog immune systems the presence of GH and GH mRNA, as well as their cellular 
distribution in the spleen, thymus, bone marrow, tonsils, lymph nodes, liver and in leucocytes 
has been reported in the literature. Although many studies have addressed the ability of the 
immune system to control pituitary GH secretion, no studies have been reported on the effect 
of the immune activation due to rhGH in healthy population. The in vitro growth-promoting 
effect of hGH upon human erythroid precursors was previously proven to be mediated by 
paracrine IGF-I.  However, the effects of rhGH on the blood rheology of healthy population 
are still to be evaluated. Hence this PhD is composed of three main investigations. Study One 
explored the effects on the blood rheology (red blood cell aggregation, deformability and 
plasma fibrinogen) parameters in healthy young males due to short-term administration of 
rhGH. These parameters can be used to estimate the efficiency of the O2 supply for working 
tissues and perhaps may indicate possible effects of athletes’ performance. Study Two 
examined the immunoregulatoty effects on: NK cell number, activity and phenotype, T cell 
subsets, CD4+/CD8+ ratio, CD4+ (Th1/Th2) cytokine production of Interleukin 2 (IL2), 
Interleukin 4 (IL4), Interleukin 6 (IL6), Interleukin 10  (IL10), Tumor Necrosis Factor - alpha 
(TNF-α) and Interferon – gamma (IFN-γ)  after short-term administration of rhGH in healthy 
young males. The immunoregulatory parameters were investigated because they provide an 
indication of the health status of the subjects. Study Three examined the regulation of gene 
expression in selected immune genes: Interleukin 6 (IL6), Interleukin 6 receptor (IL6R), 
Interleukin 10 receptor (IL10R), Perforin (PFR1), nuclear factor kappa B (NFKB) and 
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Granzyme A (GZMA). The evaluated genes are representative of immune pathways 
potentially affected by the study intervention. The correlation between these immune and 
rheologic parameters and IGF-I production were also investigated. Methodology: In Study 
One 30 males (27 ± 9 yrs) were randomly assigned to either placebo (n = 15) or rhGH (drug 
group) (n = 15). The drug group was given daily injections of 1mg/day of rhGH for seven 
days. Myrenne aggregometer was used for red blood cell (RBC) aggregation indexes. 
Deformability was evaluated by Ektacytometer and the elongation index was calculated from 
the light intensity along the major and minor axes of the diffraction image. Plasma fibrinogen 
concentration was determined quantitatively using the Von Clauss clotting method. In Study 
Two, 30 males (27 ± 9 yrs) were randomly assigned to either placebo (n = 15) or rhGH (drug 
group) (n = 15). The rhGH group was given daily injections of 1mg/day of rhGH for seven 
days. Peripheral blood mononuclear cells (PBMC) were assessed via flow cytometry and data 
was generated at baseline and Days 8, 15, 22 and 29 post injection for: NK cell number, 
activity and phenotype, T cell number, CD4+ (Th1/Th2) cytokine production of IL2, IL4, IL6, 
IL10, TNF-α and IFN-γ and CD4+/CD8+ ratio with particular attention to the possible 
correlation to IGF-I production. In Study Three, 30 males (27 ± 9 yrs) were randomly 
assigned to either placebo (n = 15) or rhGH (drug group) (n = 15). The drug group was given 
daily injections of 1mg of rhGH for seven days. The gene expression in PBMC was assessed 
by microarray and confirmed by RT-PCR for the rhGH and placebo groups. Gene expression 
data was generated at baseline and Days 8, 15, 22 and 29 post injections. All data were 
analysed using General Linear Model with repeated measures, Bonferroni correction factor 
and significance was set at p≤0.05. Results: In Study One there was a significant increase in 
the erythrocytes aggregation index post injection (day 8), in accordance with an increase in 
IGF-I levels in serum. In Study Two a significant time effect was noted in IL10 secretion 
(pg/mL) from Day 15 (P= 35.14 ± 19.93, rhGH = 26.63 ± 16.39) to Days 22 (P= 61.32 ± 
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20.41, rhGH= 74.99 ± 46.91) and 29 (P= 101.98 ± 67.25, rhGH= 107.74; ± 122.58). There 
was no correlation between IGF-I levels and immune cells numbers or activity. In Study 
Three the ratio of gene expression at each time point post baseline (Days 8, 15, 22 and 29) 
was normalised against baseline differential expression. On day 8 all the evaluated genes 
presented an up-regulation expressed as the ratio against baseline in the rhGH group 
compared with the placebo group. Interestingly, from Day 8 to Day 29 all the evaluated genes 
except IL6 remained up regulated in relation to baseline in the rhGH group. Serum IGF-I 
levels (ng/mL) increased significantly (p≤0.01) on Day 8 (0.48 ± 0.78) after injections 
compared to baseline (0.31 ± 0.07) and Days 15 (0.33 ± 0.06), 22 (0.29 ± 0.05) and 29 (0.29 
± 0.06). Conclusion: This thesis contributed to the body of the literature by generating 
unique data on the use of rhGH by healthy young subjects but mostly it provided data to 
educate and inform the effects of the use of rhGH by athletes, coaches or healthy young 
people with normal levels of GH. The results of the three studies performed have shown that 
short-term administration of 1mg/day of rhGH in healthy young males meet the three main 
criteria for the inclusion of GH on the list of prohibited substances once it was concluded that 
1mg/day of rhGH leads to acute adverse effects in the erythrocytes aggregation through the 
increase in the native blood aggregation index. Moreover, our results potentially suggest a 
chronic effect of rhGH on specific anti-inflammatory cytokine (IL10) release suggesting a 
possible advantage for the immune function of athletes and healthy young males with the 
administration of rhGH and consequently an unfair advantage in the sport performance and 
demonstrated a novel and interesting pattern of anti-inflammatory profile following rhGH 
administration. Such advantage was also shown in Study Three as rhGH was effective in up-
regulating the anti inflammatory IL10 gene pathway through the up-regulation of IL10R 
confirming the possible advantage in the performance of athletes after administration of 
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rhGH. Importantly, this thesis has shown the possibility of using genome evaluation to assess 
new pathways for detection of rhGH in healthy male athletes.   
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Chapter One 
Introduction 
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1.0 Introduction  
According to the World Anti-Doping Agency (WADA, 2009), doping can be defined as the 
presence of a prohibited substance, or its metabolites or markers, in an athlete’s bodily 
specimen. (WADA, 2009). Doping in sport has a very long history beginning in the original 
Olympic Games in 1896 (Sonksen, 2001).  
Many factors contribute to both top level and amateur athletes’ use of banned substances, 
such as the prospect of enormous earnings, the desire to become famous and raising an 
individual’s social status (Aquino Neto, 2001). However, the biological effects of substances 
such as growth hormone (GH) and its ability to improve sports performance in healthy 
population are based on anecdotal evidence.  
In clinical studies, recombinant GH is used to treat severe GH deficiency both in children and 
adolescents, such as idiopathic short stature (Bryant, et al., 2007), chronic renal insufficiency 
(Haffner, 2000), in short prepubertal children with nephropathic cystinosis to improve height 
velocity and stature height (Wuhl et al., 2001). It is also applied with significant benefits in 
children born smaller than their required gestational age, AIDS-associated wasting and mal-
absorption associated with short bowel syndrome (Napolitano et al., 2008). In patients with 
heart failure treated for 3 months with GH (4 IU every other day), GH induced a growth 
response in the diseased myocardium and reshaped left ventricular geometry with a marked 
fall in systolic wall stress. The ejection phase indices, ventricular mechanics, and cardiac 
performance improved considerably (Fazio et al., 1996).  
Johannsson and colleagues (1996) applied daily doses of recombinant GH for two years in 
patients with adult-onset GH deficiency (24 men and 20 women; aged 23-66 yr). The initial 
dose was of 4.8 µg/kg and target dose of 12µg/kg. The doses were reduced due to side effects 
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(not specified by authors) associated with taking a maximum dose of 7.8µg/kg. Bone mineral 
density (BMD) and bone metabolism were assessed with dual energy x-ray absorptiometry, 
and serum concentrations of osteocalcin, carboxy-terminal propeptide of type I procollagen, 
and carboxy-terminal cross-linked telopeptide of type I collagen. Two years after treatment 
there was a significant increase (p<0.05) in the lumbar spine L2-L4 by 3.8%, in the femoral 
neck by 4.1%, trochanter by 5.6%, and in Ward’s triangle by 4.9%. Although the dose had to 
be adapted later in the study, the results due to the treatment suggest a positive effect of the 
recombinant GH in the BMD and bone metabolism in the GH deficient population. Similarly, 
in an elderly population consisting of 12 males and 4 females aged 62-74 yrs, a single 
subcutaneous dose of GH (0.03mg/kg) 3 times per week in a 3 months trial revealed a 
significant increase in lean body mass (+3.3 ± 0.7kg, p ≤ 0.01) for the GH group as well as a 
significant increases in mean muscle mass (+3.3 ± 1.1kg, p < 0.02) (Welle et al. 1996). 
Furthermore, GH therapy has been applied in girls with Turner’s syndrome. The outcomes of 
the therapy resulted in a final height of 150.4± 5.5 cm, which was 8.4±4.5 cm more than the 
predicted height in the absence of therapy (Rosenfeld et al., 1998).  
Although studies have indicated significant positive outcomes such as increased lean body 
mass (LBM), bone mineral density (BMD) (Johannsson et al., 1996), improved cardiac 
performance (Fazio et al., 1996) in specific population groups, those desired performance 
enhancement effects of GH in athletes or healthy populations have not been successfully 
examined. The paucity of studies with healthy subjects may be due to limited availability of 
subjects to be admitted into these kind of studies, the ethical application of GH in healthy 
people, the appropriate dosage to be administering that would accurately reflect the athletes’ 
degree of misuse of GH and also the likelihood that GH may have been administrated per 
athletes concurrently with other anabolic substances which may mask the individual effects 
of GH.   
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There is evidence that the misuse of GH causes side effects such as: sodium and water 
retention (acute onset), diabetes, cardiovascular diseases, hypertension, cardiac deficiency, 
acromegaly and accelerated osteoarthritis (delayed onset) (Wallace et al., 1999, Melmed, 
2006). In addition previous researchers have identified GH receptors  present on specific 
immune cells, such as CD20+ cells (B cells), were expressed in much lower amounts in CD2+ 
cells (T cells, NK) (Badolato et al., 1994). Rapaport et al., 1995 showed that GH-R was 
expressed in more than 90% of B-lymphocytes and monocytes and in 2-20% of T cells using 
fluorescein isothiocyanate (FITC-GH), suggesting a possible stimulatory effect on cytokine 
production, cytotoxic activity of NK cells, B cell function and proliferation. 
The relationship between GH and immune cells is outlined when mice, which have 
undergone myeloablative therapy, achieve normal levels of haemoglobin, white blood cells 
and platelets much more rapidly when given GH (Tian et al., 1998). Importantly, Badolato 
and co-workers (1994) used a two-colour flow cytometric analysis with a monoclonal 
antibody specific for GHR (mAb263) and the GH ligand itself, to show the presence of GH 
receptors in B- lymphocytes, T- lymphocytes and Natural killer (NK) cells in humans. 
Although the authors had concluded that GH may have important regulatory effects on B- 
lymphocytes it also exhibited considerably lower levels of receptor expression on T-
lymphocytes and NK cells. Similarly, by administering 700 µg of human GH intramuscular 
for an average of 14 days Crist et al., (1987) evaluated natural killer cytotoxic activity 
(NKCA) in women with impaired GH secretion and concluded that daily exogenous GH 
treatment favourably increases NK cell activity. 
In agreement with the effects of GH on the immune function, Sitz (1990) after analysing four 
patients with similar disorders could associate the deficiency of GH with 
hypogammaglobulinemia (immune disorder due to low levels of immunoglobulin G (IgG), 
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immunoglobulin A (IgA) and/or immunoglobulin M (IgM)). This suggests a potential effect 
of GH on the immune system. It is also known that GH primes the oxidative burst of human 
neutrophils (Fu et al., 1992) and decreased neutrophil numbers can lead to increased rates of 
infection as a result of a decreased capacity to neutralise immunogens (Wenisch et al., 2000). 
It has been suggested by Dimitrov et al., (2004) that hormonal changes characterised in early 
nocturnal sleep (such as with GH), would be responsible for a shift towards T helper 1 (Th1) 
cytokines. Based on their results, the authors suggest that enhanced GH concentrations during 
early nocturnal sleep synergistically act to enhance Th1 cytokine activity. The question is 
whether the same effects would be characterized due to recombinant human growth hormone 
(rhGH) administration in healthy subjects. Further evidence for GH potentially exerting its 
effects is evident where GH has been shown to induce erythropoieses (Brun, 2002). However, 
the haemorheology properties of, and the effects on, GH have not been examined. Based 
upon these findings, the importance of examining the interaction of the administration of GH 
and the potential effects on the immune function of a healthy population are of significance.   
While there are anecdotal affirmations of GH misuse not only by elite athletes but also by 
recreational athletes, it is imperative to further investigate the effect of short-term 
administration of GH on blood rheology, immune function and gene expression in healthy 
active adults. The use of rhGH in the aggregation and deformability of erythrocytes, which 
impact on blood rheology (Baskurt et al., 2004) and consequently on sports performance 
needs investigation and assessment.  
Peripheral blood mononuclear cells (PBMCs) are reported to express some 75% of the human 
genome (Gladkevich et al., 2005), and have been shown to express receptors for (and thus 
potentially transcriptional profiles that are modified by) agents such as GH (Asakawa et al., 
1986). A change in gene sequence affects the morphology and phenotypic properties of 
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proteins (Lockhart & Winzeler 2000) and this regulation of gene expression is a necessary 
component of optimal eucaryotic function. This can be achieved by adjusting protein activity, 
generating protein diversity and controlling the concentration of a protein in a particular area 
(Orphanides & Reinberg 2002). In particular, the assessment of the expression of genes 
linked to the activity of the immune system may represent the effects of the use of short-term 
administration of rhGH in healthy young males at the gene level. 
Based upon the limited previous investigations examining GH and their potential effect on 
healthy population the proposed research is of particular significance for providing evidence 
of the effects of rhGH in the blood rheology (aggregation, deformability), on immune cells 
and their function, and in the gene expression of specific immune genes of healthy young 
males. 
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Chapter 2 
Review of the literature 
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2.1 Growth hormone  
Growth hormone (GH, somatotrophin) is a single chain polypeptide containing 191 amino 
acids, two disulfide bridges and four helical structures (Nussey and Whitehead, 2001). The 
half life of GH in circulation is approximately 20 minutes (Veldhuis et al., 1993). It circulates 
in several forms that vary according to size (molecular weights of 20 KDa and 22 KDa), 
isoelectric point (acidic forms), oligomers (up to pentamers) and fragments (molecular 
weights of 12 KDa and 16 KDa) (Nussey and Whitehead, 2001). In addition, approximately 
50% is bound to the extracellular domain of its receptor (also termed the GH-binding protein, 
GHBP).  
There are two molecular variations of the GH receptor, full-length and truncated form. The 
full-length form belongs to the Class I cytokine receptor family (Nussey and Whitehead, 
2001). These are all proteins of the single transmembrane domain in which the intracellular 
domain is associated with a protein tyrosine kinase known as Janus kinase (JAK), that 
phosphorylates signal transducers and activator of transcription (STAT) kinase (the JAK-
STAT signalling pathway) initiating a cascade of protein phosphorylation events (Nussey and 
Whitehead, 2001).  
Classically, the synthesis and secretion of GH has been thought to be controlled by two 
hypothalamic neurohormones, stimulatory growth hormone-releasing hormone (GHRH) and 
inhibitory somatostatin (inhibits GH’s secretion) (Bouillanne et al., 1996). However, Ghrelin 
is another hormone found to be responsible for the release of GH (Kojima et al., 1999). 
Ghrelin was shown to function in humans more powerfully as stimulus for GH production 
than GHRH (Arvat et al., 2000). The mRNA for Ghrelin and its receptor were found in all 
human tissues including lymph nodes, circulating lymphocytes and spleen (Gnanapavan et 
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al., 2002). Although in this study the actual class of lymphocytes was not specified, the 
potential for GH to elicit a response on immune cells is evident.   
2.2 GH receptors 
Growth hormone receptor (GHR) consists of a single chain of 638 amino acids including an 
18 amino acid signalling peptide, a 246 residue extracellular cytoplasmic domain, a small 24 
amino acid transmembrane domain and a 350 residue intracellular cytoplasmic domain 
(Postel-Vinay, 1994). While the liver is one of the most abundant sources of GHR, improved 
detection techniques combined with analysis of mRNA expression, provide evidence that 
GHR are present in adipose tissue, heart, kidney, stomach, small intestine, colon, pancreas, 
lung, brain, cartilage, muscle, adrenal gland, skin, lymphatic cells, testis, ovary, corpus 
luteum, mammary gland and specifically the immune cells (Mathews et al., 1989; Tiong and 
Herington, 1989; Lobie et al., 1990; Tiong and Herington, 1992). Studies using 
Crystallography have demonstrated that the addition of GH to GH binding protein (GHBP) 
results in a complex in which two GHBP molecules are bound by a single GH molecule 
(deVos et al., 1992). The binding occurs in a sequential manner where one GHBP molecule 
binds to site 1 on GH and then the second GH site becomes available for a second GHBP 
molecule to bind.  
2.3 GH regulation 
Growth hormone concentrations (22KDa) rise after birth reaching level concentrations higher 
(4 days old neonates 11.20 ± 1.97 ng/mL) than that of healthy adults (12 men, 8 women), 
aged 20 ± 0.3 years old (2.43±0.72 ng/mL) (Radetti et al., 2000). The most profound effects 
are by stimulating proliferation of cartilage in the epiphyseal plates of long bones before they 
fuse. In addition to stimulating linear growth, GH also increases total bone mass and mineral 
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content by increasing the activity and number of bone modelling units (Nussey and 
Whitehead, 2001).  A peak period is observed during puberty and there is a marked decline in 
old age. In the adult human, approximately five pulses of GH are secreted during a 24 h 
period with a largest peak occurring at the onset of sleep. The mean concentration of 
circulating GH varies throughout life (Nussey and Whithead, 2001) and in healthy adults GH 
concentrations are less than 3 ng/mL (Shimizu et al., 2005). In normal subjects (6 men and 6 
women, aged 20-47 yr) under physiological conditions, plasma GH, as measured by IRMA, 
was detectable at all time points during 24h evaluation and ranged from 40 to 19.695 ng/L 
(Winer et al., 1990).  
Growth hormone has direct actions on the liver, adipose tissue and muscle although many of 
its actions are mediated by increasing the synthesis and release of insulin-like growth factors 
(IGFs) (Savino et al., 2002). Insulin Growth Factors (IGFs) stimulates DNA, RNA and 
protein synthesis in many organs such as thymus (Savino et al., 2002), increasing both their 
size and function including thymocyte proliferation and migration (Savino et al., 2002). The 
Growth Hormone-stimulated release of IGFs from the liver also has important feedback 
effects on the control of GH release, inhibiting it. Growth hormone also stimulates the 
synthesis and release of insulin-like growth factor binding proteins (IGFBPs) which bind 
circulating IGFs (Guler et al., 1989). This binding provides a reservoir of circulating IGFs. 
Normal concentrations of GH are also required to sustain normal pancreatic islet function. 
Thus, during GH deficiency insulin secretion declines whilst an excess of GH reduces 
insulin-dependent glucose uptake causing a rise in insulin secretion to compensate for the 
GH-induced resistance (Guler et al., 1989).  
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 2.4 Clinical uses of GH 
Growth hormone therapy is the standard of practice by Food and Drug Administration (FDA) 
approved for children of short stature with classic GH deficiency, chronic renal failure, and 
Turner's syndrome. The Canadian Growth Hormone Advisory Committee conducted a study 
in 2005 where 154 girls with Turner Syndrome (TS) (aged 7–13 years) were randomly 
assigned to receive GH (0.3 mg/kg/week, maximum weekly dose 15 mg) or no treatment 
until height velocity was less than 2 cm/year and bone age was greater than 14 years. After a 
mean follow up period of 5.7 ± 1.6 years, the GH group achieved a final adult stature 7.2 cm 
taller than the control group (The Canadian Group Hormone Advisory Committee, 2005). 
The results suggest that replacement with GH to GH deficient population has positive 
outcomes and is standard of practice for treatment.    
Adamopoulos et al., (2003) studied the effects of subcutaneous administration of GH (4 IU 
GH every other day) in 12 idiopathic dilated cardiomyopathy (DCM) patients (50± 4 years) 
in a 12- week treatment period against a 12-week period without treatment with GH on 
circulating pro-inflammatory/anti-inflammatory cytokine balance, and whether these GH-
induced immunomodulatory effects were associated with the improvement of left ventricular 
(LV) contractile performance in DCM patients or not. The authors demonstrated, through 
enzyme-linked immunosorbent assay (ELISA), that a 3-month therapy with GH causes a 
significant decrease in the circulating proinflammatory cytokines (tumour necrosis factor-α 
(TNF- α), interleukin-6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF) 
and its soluble receptor GM-CSFR), chemotactic chemokines, macrophage chemoattractant 
protein-1 (MCP-1) and soluble adhesion molecules intercellular adhesion molecule-1 
(sICAM-1) and vascular cell adhesion molecule-1 (sVCAM-(1)), as well as an increase in the 
serum anti-inflammatory/pro-inflammatory balance (IL-10/IL-6, IL-10/TNF- α and TGF-
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β2/TNF-α) whilst enhancing contractile reserve and reducing LV dimensions. Those results 
suggest an important role of GH at immunomodulatory effects for cytokines balance.    
In another clinical area, Haffner et al., (2000) determined the final adult height of 38 children 
with chronic renal failure who were treated with GH for up to nearly nine years. The results 
were compared to 50 similar children who did not receive the GH therapy because their 
growth retardation at the beginning of the study was less marked than that of the treated 
children. The mean final adult height of the growth hormone–treated children was 1.6±1.2 
SD below normal, which was 1.4 SD above their standardized height at base line (P< 0.001). 
Differently, the final height of the untreated children (2.1±1.2 SD below normal) was 0.6 SD 
below their standardized height at base line (P<0.001).  
Similarly, Li and co-workers (2008) evaluated the efficacy and safety of rhGH in the 
treatment of 114 patients with chronic liver failure, where 56 patients in the rhGH treatment 
group received 4.5 IU of rhGH intramuscularly daily for 4 weeks while 58 patients were 
assigned in the control-treatment group and 15 healthy subjects served as controls. The study 
showed the efficacy of rhGH treatment was 87.5% (vs. 38.1% in the controls-treatment 
group, p < 0.01) and the survival rate of the rhGH treatment and control-treatment groups 
after 2 weeks, 1 month, 3 months, and 6 months of treatment was 98.21% vs. 75.86%, 
91.07% vs. 62.07%, 66.07% vs. 22.41%, and 55.36% vs. 13.79%, respectively. The response 
from the use of GH in clinical treatments is widely observed as previously shown however to 
date experiments have not been conducted in healthy populations.   
2.5 Doping with GH in sport 
Studies examining the potential performance enhancing effect of GH are limited provided 
that GH is an illegal substance part of the list of prohibited substances by the World Anti-
Doping Agency (WADA). Administration of rhGH in a double-blind study (16 males of 21-
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34 yr) prior to and during a 12-week programme of daily resistive weight training (75-90% 
maximum strength with low repetition (4-8 times) for 4 sets/session 5 days/week) while 
receiving 40 µg rhGH.kg-1.day-1 or placebo resulted in no significant difference between the 
two groups with regards to muscle strength, size and protein synthesis (Yarasheski et al., 
1992). In this study muscle strength was determined via maximum amount of weight lifted on 
each of the Nautilus exercise devices (N.m). The maximum force produced by the knee 
extensor and flexor muscles during maximum voluntary concentric (60°/s) and isometric 
contractions on Cybex dynamometer, while whole protein turnover was measured by 
[15N]glycine was administered orally (0.5mg 15N kg-1.day) every 3 h during the last 60 h of 
each 10-day controlled protein diet period. The 15N enrichment in total urinary N was 
determined, and the rates of whole body protein turnover, synthesis, and breakdown were 
calculated as previously described (Steffee et al., 1976). 
Similarly, no significant difference (p>0.05) was found in bone mineral accumulation 
measured by dual-energy X-ray absorptometry. Yarasheski et al., (1997) evaluated 18 elderly 
healthy men (67± 1 yr) during 16 weeks of progressive resistance training (75-90% 
maximum strength, 5-10 repetitions/set, 4 sets/day, 4 days/week). Participants in this study 
received either daily 12.5 or 18 µg/kg GH, (n=7) or placebo (n=11). The daily dose of GH 
did not enhance the whole body or regional bone mineral density (Yarasheski et al., 1997). 
Similarly, in support of these previous studies Yarasheski (1993) examined 7 healthy young 
(23 ± 2 yr; 86.2 ± 4.6 kg) experienced weightlifters for 14 days with subcutaneous GH 
administration (40 microgram.kg-1 x day-1). There was no increase in the rate of muscle 
protein synthesis or reduced rate of whole body protein breakdown determined during a 
constant intravenous infusion of [13C]leucine (Yarasheski et al., 1993).   
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Based upon these limited findings there seems to be little evidence to suggest increased sport 
performance after GH administration. However, it is highly plausible that elite athletes may 
be using GH in dosages ranging from approximately 15 to 180µg/kg per day, which would be 
higher than dosages used in most experimental studies (Saugy et al., 2006). Furthermore, 
anecdotal reports of sports doping regimens suggest that GH is not typically used as a single 
agent, but rather is often combined with other substances, such as anabolic androgenic 
steroids, insulin, and anti-estrogens (Fainaru-Wada, 2006) suggesting that they may have 
different benefits and risks when taken together.  
2.6 IGF-1 
Insuline growth factor-I is a polypeptide promoting growth cellular consider, consequently, 
essential for the normal development. The two ligands, IGF-I and IGF-II, are mitogenic 
peptides that are highly homologous to each other and share structural homology with insulin. 
The insulin-like growth factor system is composed of a family of interacting ligands, 
receptors and binding proteins (Daughaday et al., 1989). The hepatic synthesis of IGF-I is 
largely GH dependent, whereas the synthesis of IGF-II is relatively independent of 
GH. (Khandwala et al., 2000) It was recently shown that IGF-1 is inversely correlated with 
IL-6 plasma levels (Barbieri et al., 2003). In a longitudinal survey it has recently been shown 
that older women having low serum levels of IGF-I and high serum levels of IL-6 have the 
highest risk of disability and mortality, in comparison with women who have low levels of 
IL-6 and high levels of IGF-1 (Cappola et al., 2003). 
2.7 Immune system 
Studies confirming GH influences on the immune system, originated prior to 1987 from 
findings in hypophysectomised animals (rodents) as well as in humans with deficiencies in 
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pituitary hormones (Gala, 1991). Immune cells are able to produce GH (Varma et al., 1993), 
IGF-I (Nyman and Pekonen, 1993) and IGF-binding proteins (Nyman and Pekonen, 1993). 
Growth hormone acts directly on many tissues by binding to the GHR (Smit & Carter-Su 
1996). 
Both innate immunity and adaptive immune responses depend on the activities of leucocytes 
(Murphy et al., 2007), cells of the immune system that defend the body against both 
infectious disease and foreign pathogens. Innate immunity largely involves activities of 
granulocytes and macrophages (Murphy et al., 2007). Cells of the adaptive immune response 
include lymphocytes, which have the capacity to promote life-long immunity after exposure 
to disease or vaccination. The innate and adaptive immune systems together provide a 
remarkably effective defence system (Murphy et al., 2007). Many infections are successfully 
eliminated by the innate immune system; others that cannot be resolved by innate immunity 
trigger adaptive immunity and are then overcome successfully and prevented from recurring 
by immunological memory (Cooper and Alder, 2006). Several different types of leucocytes 
exist, all produced and derived from hematopoietic stem cell in the bone marrow (Cooper and 
Alder, 2006).  
The number of leucocytes in the blood is often an indicator of disease. There are normally 
between 4×109 and 11×109 white blood cells in a litre of blood, making up approximately 1% 
of blood in a healthy adult (Alberts, 2005). There are two major types of lymphocyte: B 
lymphocytes, which when activated differentiate into plasma cells that secrete antibodies; and 
T lymphocytes.  
This project selected the following immune cells to be investigated: NK cell number, activity 
and phenotype, T cell number, CD4+ (Th1/Th2) cytokine production of IL2, IL4, IL6, IL10, 
TNF-α and IFN-γ and CD4+/CD8+ ratio.  
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2.7.1 T Lymphocytes 
The T cells contribute to immune defences in a direct way where it regulates immune 
responses; or directly attack infected or cancerous cells.  In most cases, T lymphocytes only 
recognize an antigen if it is carried on the surface of a cell by one of the body’s own or major 
histocompatibility complex (MHC), molecules (Murphy et al., 2008).  The T lymphocytes 
population is grouped in two; helper T lymphocytes which mainly express cluster of 
differentiation four (CD4+) and cytotoxic T lymphocytes which primarily express cluster of 
differentiation eight (CD8+) surface proteins (Murphy et al., 2008). The CD4+ T lymphocytes 
have a regulatory overall effect on immunity and orchestrate their activity through diverse 
cytokine secretions or by direct intercellular contact (Murphy et al., 2008).  The CD8+ 
cytotoxic T lymphocytes are effector cells that secrete and respond to cytokines targeting 
infected cells to induce programmed cell death (Kimata and Yoshida, 1994). The T cell 
immunological activity and response can be monitored by assessing the CD4+/CD8+ ratios 
that illustrate critical T cell functions (Kimata and Yoshida, 1994). Previous in vitro studies 
have shown that GH effects on normal and neoplastic human T cells enhanced proliferation is 
mediated by local increase expression of IGF-I (Geffner et al., 1990; Merchav et al., 1988; 
Mercola et al., 1981; Mosmann and Coffman, 1989). 
2.7.2 CD4/CD8 ratio 
The CD4/CD8 lymphocyte ratio in blood is used in the diagnosis of HIV infection (Pahwa et 
al., 2008; Butt et al., 2007; Shearer et al., 2007) and autoimmune disorders such as 
rheumatoid arthritis or vitiligo (Hussein et al., 2008; Pichler et al., 2009). The ratio of 
CD4/CD8 is used as a marker of the immune system function (Evans et al., 2004) 
determining the ratio of the T helper/suppressor profile.  
 
38 
 
2.7.3 Th1 and Th2 
The difference between these two subtypes of lymphocytes pertains to the type of cytokine 
they produce; Th1 cells secrete interleukin four (IL-4) and Th2 cells secrete interferon-
gamma (IFN-γ) (Mosmann, 1996). Naïve T lymphocytes and mature T lymphocytes in 
general express certain co-stimulatory receptors that are important for fighting against 
infection (Murphy et al., 2008). Th1 responses include cell mediated reactions that are 
important for dealing with cellular pathogens, whereas Th2 responses regulate production of 
antibodies in response to extracellular pathogens and mediate allergic processes (Romagnani, 
1999). An example of a co-stimulatory receptor is CD28 which is induced during infections. 
It is essential for the propagation of T cells and cytokines (Murphy et al., 2008). In the 
presence of an infection, professional antigen presenting cells (APC) such as dendritic cells 
or cytokines bind to the CD28 expressed on the surface of the naïve T cells, thus activating 
the T cell (Murphy et al., 2008).  
2.7.4 Natural Killer 
A third lineage of lymphoid cells, called natural killer (NK) cells, lack antigen specific 
receptors and are part of the innate immune system (Perricone et al., 2008). They are able to 
recognise and kill some abnormal cells, for example some tumour cells and virus-infected 
cells, and are thought to be important in the innate immune defence against intracellular 
pathogens (Murphy et al., 2007). There are two main types of NK cells; 90% of these cells 
are classified as CD56dimCD16+ while the remaining 10% are comprised of CD56brightCD16- 
(Farag et al., 2002). CD56brightCD16- facilitates the production of cytokines while 
CD56dimCD16+ induces both natural cytotoxicity and Antibody-Dependent Cell-Mediated 
Cytotoxicity (ADCC), hence there are high levels of lytic granules in CD56dimCD16+ 
compared to CD56brightCD16- (Farag et al., 2002). 
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Firstly described by Canty and Wunderlich (1970), the 51Cr release assay has been criticised 
for requiring a radioactive isotope and for not permitting the characterization of the cells 
involved in the cytotoxic reaction (Lecoeur et al., 2001). Additionally the chromium (51Cr) 
release assay is more expensive and the spontaneity involved in this protocol makes it more 
disadvantageous (Neri et al., 2001). The proposed method measures the ability of the NK 
cells to lyse the erythroleukemia cell line known as K562. The principle behind this method 
is that the NK cells once in contact with the K562 cells cause them to undergo apoptosis by 
activating cell death pathways. Therefore this method assess the number of K562 that have 
undergone apoptosis in the presence of NK cells and compares them to a population of live 
K562 that were not induced to undergo apoptosis with NK cells (Zamai et a., 1998). 
2.8 Immune cell function and GH 
Hormones are immunomodulators that alter immune system sensitivity. It is clear that GH 
exerts stimulatory effects in central and peripheral lymphoid organs being considered a potent 
immunomodulatory hormone (Auernhammer, 1995). All hematopoietic lineages found in 
bone marrow, including B lymphocytes, macrophage, T lymphocytes and granulocytes 
precursors, express GH receptors to various extents (Dardenne et al., 1998). Several studies 
have demonstrated that, exogenous GH may improve a variety of immune functions 
including B lymphocytes responses and antibody production (Kimata, 1994), NK activity 
(Stephenson et al., 1991), macrophage activity (Gaytan et al., 1994), T lymphocytes function 
and neutrophil function (Fu et al., 1992). See Figure 1. 
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Figure 1. Growth hormone and ghrelin in the immune system (Hattori, 2009).  
2.9 GH receptors and expression on immune cells 
Growth hormone binding protein (GHBP) first reported in 1964, corresponds to the extra 
cellular domain of the GHR (Kelley and colleagues., 2007). In IM-9 lymphocytes, GHBP are 
formed through proteolysis and it is suggested that it shows antagonistic properties in vitro 
and agonistic in vivo (Jones & Clemmons, 1995). It was reported that human lymphocytes 
secrete GH releasing hormone (GHRH) and IGF-I expressing their respective receptors 
(Weigent, 1991). The affinity constant of GHR, by the Scatchard analysis is 1.3-1.5 x 10-
9l/mol and the receptor numbers is usually from 4000-7000 per cell (Cunningham et al., 1990; 
Fu et al., 1992). The presence of GHR on peripheral blood mononuclear cells can be 
obscured by the fact that GH can bind to prolactin receptors as well (Cunningham et al., 
1990; Fu et al., 1992).  
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As previously evaluated, GH may have a multifactor influence in the immune cells number 
and function and this project aims to evaluate these effects in healthy human population.  
2.10 Haemorheology 
Haemorheology is the science that describes the flow characteristics of the blood (El Sayed et 
al., 2005). Essential delivery substrates in cells and the removal of the by products of cell 
metabolism are related to microcirculation and are influenced by the microvascular network 
(Kamm, 2002). Erythrocytes form the majority of the blood constituents (up to 98%); hence 
any change in their flow behaviour affects the blood flow through the cardiovascular system 
and consequently the blood circulation (Sanjay, 2002).  
The properties of erythrocytes include erythrocyte deformation by shear force reducing the 
flow resistance and erythrocyte aggregation resulting from an increase in flow resistance 
(Kamm, 2002). 
A relationship between GH and the rheologic function of circulating RBC was suggested by 
Engstrom and colleagues (1990). After analysing hypophysectomy rats with GH treatment 
(1mg/kg/day continuously infused in female rats during 21 days) RBC deformability and 
filterability were normalised (Engstrom et al., 1990), suggesting a relationship properties 
between GH and blood rheology. Importantly, GH has been shown to induce erythropoiesis 
(Brun, 2002). It is these limited studies that indicate GH may play an important role in 
influencing haemorheology, however RBC aggregation and deformability have not been 
determined.  
2.10.1 Erythrocyte Aggregation 
Erythrocyte aggregation is one of the most important factors which determine the blood flow 
at low flow shear rates in the microcirculation (Skalak, 1981). The microcirculation helps to 
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regulate the O2 supply to the tissues which can be consequently influenced by the aggregation 
of the erythrocytes. The growth process of the structure of the aggregates depends on the 
deformation of the shape of the outermost cell (concave or convex) available for attachment 
to individual erythrocytes (Skalak, 1981). Red blood cells (RBC) in the presence of plasma 
proteins, principally fibrinogen, may aggregate to form rouleaux formations (Shalak, 1981). 
Of particular importance are the rheological properties of erythrocytes, since erythrocytes 
constitute for up to half of the volume of the blood (Maeda, 1996).  
The extent of RBC aggregation is determined by opposing forces: the repulsive force 
between the negatively charged cells, the cell-to-cell adhesion induced by plasma proteins, 
and the disaggregating shear force generated by blood flow (Chien, 1982). Red blood cell 
aggregation is thus dependent on both plasma factors and on cellular factors. It is agreed that 
the blood flow is sufficient for dispersion of RBC aggregates (Chien 1982). It is assumed that 
this process is dependent on both the size of RBC aggregates and the cohesive forces within 
aggregates, expressed by the shear stress required to disperse them.  
Red blood cell aggregation is increased in various conditions associated with an 
inflammatory response (Weng, 1996). At low shear rate, an increase in red cell concentration 
promotes red cell aggregation, which increases effective cell volume and blood viscosity 
(Skalak, 1984). At high shear rate, an increase in red blood cell concentration promotes 
deformation of red cells, which decreases effective cell volume and hence compensates for 
the increase in viscosity (Lowe, 1980). Claustres and co-workers (1987) demonstrated the 
delivery of substrate and O2 to exercising muscle could be increased by the administration of 
GH and IGF-I, suggesting a possible interaction of GH and haemorheology, however further 
studies need to be conducted to assess the effect of administration of GH on blood rheology 
of healthy patients. This link between body composition, haemorheology and GH can be 
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justified due to the GH being considered a major regulator of body content in fat and water 
(Brun, 2002).  
Aggregation of RBCs can be quantitatively measured by evaluating the RBC sedimentation 
rate (Houbouyan et al., 1998), zeta sedimentation rate (Bull & Brailsford, 1972), low-shear 
viscometry (Baskurt & Meiselman 1997), using a flow chamber analysis (Chen et al., 1994), 
ultrasound back scattering (Boynard et al., 1987) and photometry analysis (Hardeman et al., 
1994). The Myrenne aggregometer is a type of back scattering instrument used in 
determining RBC aggregation. This instrument simultaneously disseminates pre-existing 
aggregates via cone rotation in a transparent cone-plate chamber at a shear speed of 600seg-
1/10sec (Vaya et al., 2003). Two mode measurements are generated from this instrument 
relating to the speed of rotation of the cone at stasis (M) and at 3s-1(M1) (Vaya et al., 2003). 
The increase in aggregation corresponds to an increase in these two indices (Vaya et al., 
2003). The results can either be recorded after 5 or 10 seconds after the cone has halted its 
rotation (Vaya et al., 2003).  
2.10.2 RBC Deformability 
Cell deformability is characterised by general measurement of cell biology and physical 
forces applied to the red blood cell that influences macro- and microcirculation (Musielak, 
2009). Growth hormone, IGF-I and IGF-II are shown by early studies to stimulate 
erythropoiesis (Golde, 1977; Fruhman, 1954). Additionally GH-IGFI axis has great effects on 
body composition, fuel and fluid metabolism and it is likely to influence the viscosity of 
blood, consequently, RBC rheology, (Brun et al., 2002) and consequently performance of 
athletes.  
The close observation of RBC deformation requires the development of certain instrument 
that measure deformability, for this reason instruments such as the micropore filtration, high-
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speed centrifugal deformation, micropipette aspiration and the Rheoscope have been 
developed (Pfafferott et al., 1985). The most extensively used techniques however are RBC 
filtration, ektacytometry and Rheoscope (Shin et al., 2004) which quantifies pressure across 
the RBC membrane or the time it takes for a particular amount of RBC to move through a 
vessel (Shin et al., 2004). One limitation with this method is the lack of a standard with which 
to compare the measured values (Shin et al., 2004). 
The rheoscope conversely deforms RBC through the application of shear flow forces (Dobbe 
et al., 2002).  It employs the use of the microscope and counter rotating plates on which the 
RBCs are placed (Dobbe et al., 2002). Images are projected on to a video camera and 
adjusted using both bright field stroboscopic illumination and an interference filter (Dobbe et 
al., 2002). The apparatus, however, is still quite cumbersome and requires great operator skill 
(Mohandas et al., 1980). 
The Ektacytometry on the other hand applies laser diffraction procedure to RBC while 
subjecting them to various types of stresses from a small amount of blood (Bessis & 
Mohands 1980). Rheoscan-D is presently the latest version of ektacyometer being used to 
measure deformability in erythrocytes. The Rheoscan-D is a slit ektacytometer having a laser, 
a video camera, a pressurised slit medium and a vacuum generating apparatus (Shin et al., 
2005). A suspension of blood is placed in a sample chamber which allocates the blood in to 
the slit (Shin et al., 2005). In the slit a laser beam is transmitted which becomes diffracted 
once it comes into contact with the RBCs (Shin et al., 2005). As pressure in the slit 
compartment decreases or increases the RBC change their conformation (Shin et al., 2005).  
2.10.3 Fibrinogen 
Fibrinogen is a 340 kDa dimeric glycoprotein composed of three pairs of non-identical 
polypeptide chains denoted Aα, Bβ, and γ (Henschen and Lottspeich, 1977). Previouly 
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described by Reinhart (2003) fibrinogen is required in the final step of the coagulation 
cascade and transformed into fibrin through thrombin. Furthermore, fibrinogen is considered 
a major determinant of plasma viscosity and erythrocyte aggregation (Reinhart et al., 2003). 
Furthermore, fibrinogen has been considered the major plasma protein coagulation factor 
(Lowe et al., 2004). In Larsson and colleagues (1984) during 13.5 years of follow up with 
almost 800 men aged 54, fibrinogen level was suggested to have an important role in the 
development of stroke and myocardial infarction for its coagulations effects.  
 
2.11 Animal studies with GH 
Studying animals can represent a model for the investigation of the relation of GH and 
immune system. Growth hormone plays an important role in the regulation of humoral and 
cellular immune responses due to existence of GH receptors (GHR) on immune cells such as 
B, T lymphocytes and macrophages (Murphy et al., 1992). This has been observed in GH 
deficient animals by several studies (Gala et al., 1993). Growth hormone receptors are 
expressed on immature CD4-CD8- double negative and CD4+CD8+ double positive 
thymocytes, suggesting that GH could have a direct influence in the early stages of T 
lymphocytes differentiation, thus confirming the role of GH hormone in T lymphocytes 
development (Gagneraud et al., 1993). Growth hormone receptors belongs to the cytokine-
GH-PRL receptor superfamily, which includes receptors for many cytokines involved in the 
growth and differentiation of lympho-hematopoietic lineages, and GHR could mediate 
similar effects (Gagneuraud et al., 1993).  
Seiva and colleagues (2008) using 25 male Wistar rats with heart failure, applied two 
different doses of rhGH (1mg/kg/day and 2 mg/kg/day) subcutaneously for two weeks and 
concluded that, GH effects dose-dependent with both tested doses which did not affect the 
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heart dysfunction. The higher GH dose, 2 mg/kg, exerted detrimental effects related to energy 
metabolism and oxidative stress, while the smaller dose, 1 mg/kg GH, exerted beneficial 
effects; enhancing antioxidant defences, reducing oxidative stress and improving energy 
generation in myocardium of rats with heart failure.  
As shown in previous animal studies mentioned (Gala et al., 1993; Gagneraud et al., 1993) 
GH may affect the function of immune cells and erythropoiesis. This is the first study to 
evaluate those effects in healthy human subject’s immune cells and erythrocytes. 
 
2.12 Gene expression 
The primary step in gene expression is the transformation of deoxyribonucleic acid (DNA) to 
messenger ribonucleics acid (mRNA) through the process of transcription. This is then 
followed by the conversion of the mRNA information to proteins in a cellular process known 
as translation (Orphanides & Reinberg 2002). Messenger RNA (mRNA) is the link between 
DNA and proteins whereby measuring the change in transcription level between treated vs 
non-treated states has become an increasingly useful tool used to study gene transcription and 
expressional changes leading to a better understanding of biological processes (Bustin et al., 
2004). 
Regulation of gene expression is a necessary component of optimal eucaryotic function. This 
can be achieved by adjusting protein activity, generating protein diversity and controlling the 
concentration of a protein in a particular area (Orphanides & Reinberg 2002). These 
procedures are necessary for intracellular signalling via phosphorylation of proteins, 
metabolic functions of various proteins and cellular activation (Orphanides & Reinberg 
2002). 
Figure 2: The process of transcription and translation (Orphanides & Reinberg 2002). 
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 White blood cells (WBCs) express tens of thousands of genes, whose expression levels a
modified by genetic and external factors. A number of authors (Maas et al., 2002; Whitney
al., 2003; Baechler et al., 2004; Gregersen 2003) have recently explored the use of peripher
blood cells as a readily available source of material for gene expression analyses in huma
The mechanism by which inducers of drug metabolism and drug transport exert their effec
in humans in vivo is poorly defined because sampling of tissues of interest, such as the liv
is by necessity restricted. However, use of the human lymphocyte, a readily obtainable blo
fraction may be valuable in quantifying induction events on an individual basis. This stu
will consider PBMC’s for evaluating the effects of rhGH on the expression of gen
associated with the immune system in healthy young males. This investigation will use rea47 
 
time RT-PCR to monitor the expression pattern of selected genes in human haematopoietic 
cells exposed to rhGH. The potential application of cDNA microarray and/or quantitative 
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RT-PCR (Q-RTPCR) analyses, using samples obtained from leucocytes has been recognised, 
and provides theoretical support for this approach in the context of selected immune genes 
expression after short-term administration of rhGH in healthy subjects. On the RT-PCR the 
reverse transcription is the first step, the exponential amplification via RT-PCR provides a 
highly sensitive technique where a very low copy number of RNA molecules can be detected 
(Chelly et al., 1989) 
2.13 Genes related to GH 
In the present study the aim was to determine if selected genes related to the activity of 
immune system (IL6, IL6R, IL10R, PFR1, NFKB and GZMA) and their regulation are 
influenced by short-term GH administration. As there are speculations of the use of rhGH by 
healthy young males, it is important to further investigate the cellular effects of rhGH on the 
immune function at the cellular level of healthy young males.  
The protein encoded by Perforin (PFR1) has structural and functional similarities to 
complement component 9 (C9). Like C9, this protein creates transmembrane tubules and is 
capable of lysing non-specifically a variety of target cells. This protein is one of the main 
cytolytic proteins of cytolytic granules, and it is known to be a key effector molecule for T-
cell- and natural killer-cell-mediated cytolysis. According to Liu et al., (1989), PFR mRNA 
was detected in most T blast populations.  
Nuclear factor kappa B (NFκB) is a protein complex that controls the transcription of DNA 
and is found in almost all animal cell types. It plays a key role in regulating the immune 
response to infection. Through a cascade of events, the kinase complex is activated and NFκB 
is able to enter the nucleus to up regulate genes involved in T cell development, maturation, 
and proliferation. Thus, evaluation of the expression of NFκB up or down-regulation may 
generate indication of the influence of the rhGH in the athlete immune function.  
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Interleukin 6 (IL6) encodes a cytokine that functions in inflammation and the maturation of B 
cells (Yasukawa et al., 1987). The protein is primarily produced at sites of acute and chronic 
inflammation, where it is secreted into the serum and induces a transcriptional inflammatory 
response through interleukin 6 receptor. Its receptor system consists of two molecules: a 
ligand-binding molecule and a non-ligand-binding signal transducer, both part of the cytokine 
receptor family (Omoigui, 2007). 
Interleukin 10 Receptor (IL10R) is a heterotetramer composed of 2 of each of the receptor 
chains which belong to class II cytokine receptors (Liu et al., 1994). Interaction of IL10 with 
the IL10R complex stabilizes dimerization of IL10R subunits, activates phosphorylation of 
the receptor-associated Janus tyrosine kinases, Janus kinase (JAK) 1  induces signal 
transducers and activators of transcription (STAT) 3- and STAT1-mediated signal 
transduction as described by previous studies Riley et al., (1999) and  Donnelly et al., (1999). 
Granzyme A (GZMA) is located in the granules of cytotoxic T and NK cells.  The pathway of 
T lymphocyte cytotoxicity was described by the perforin/granzyme pathway (Valerio et al., 
1997). In data, in vivo analysis of cytotoxic CD4+ T cells indicates that they have lytic 
granules containing cytotoxic factors such as granzymes and perforin (Appay, 2004). It was 
shown in the literature that CD8+ cytotoxic lymphocytes and NK cells use the 
perforin/granzyme pathway as a major mechanism to kill pathogen-containing cells and 
tumor cells (Shresta et al., 1998).  
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2.14 Significance 
This is the first study to evaluate the possible effects of short-term administration of rhGH to 
healthy young males on the rheology of the blood as it is a great influence in the status of the 
delivery of substrates as well as O2 to the tissue and consequently a compulsory factor for the 
characterization of the healthy status of the blood flow.  
According to the “open window” theory (Nieman, 2000), the immune system of athletes may 
vary due to training and competitions status. Since there is a lack of information on how 
exogenous rhGH can possibly affect the immune numbers and function of healthy population 
this study become mandatory for such understanding. 
This research had particular significance in providing evidence for changes in immune cells 
and function, due to the short-term administration of rhGH in healthy subjects. Growth 
hormone binding was first detected on a human B cell lymphoma (IM-9) lymphocyte cell line 
(Lesniak et al., 1974) and subsequently on human PBMCs (Lymphocytes and monocytes) 
(Kiess et al., 1985) as such this study investigated whether changes in gene transcription 
within PBMCs provide evidence on the possible effects of the use of rhGH in healthy young 
males. This is a stringent study that considers rhGH effect on lymphocytes number and 
function, haemorheology and gene expression in healthy active adults.  
 The objectives of this project were to:  
1.  Assess possible alterations in blood rheology due to short-term recombinant human 
GH (rhGH) administration to evaluate the effects in aggregation, deformability, 
plasma fibrinogen and IGF-I levels in healthy young males  
2.   Evaluate the immunomodulatory effects of short-term administration of recombinant 
human GH (rhGH) in healthy young males in relation to NK cell number, activity and 
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phenotype, T cell number, cytokine production of IL-2, IL-4, IL-6, IL-10, TNF-α and 
IFN-γ and CD4+/CD8+ ratio  
3. Evaluate the effects of short-term administration of recombinant human GH (rhGH) 
in healthy young males on the gene expression of selected genes whose activity is 
associated with the function of immune system (IL6, IL6R, IL10R, PFR1, NFKB and 
GZMA). 
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Chapter 3 
Research studies of this thesis 
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3.0 Research studies of this thesis 
The following chapter describe the studies conducted aiming to answer the stated research 
questions.  
3.1 Study One 
The following paper was published in the Journal of Clinical Haemorheology and 
Microcirculation 2010 (ISSN 1386-0291). Study one evaluated the hemorheological effects 
of short-term administration of human recombinant growth hormone (rhGH) in healthy 
young males. The study one also correlated the hemorheological parameters evaluated to 
IGF-I in serum. 
3.2 Study Two 
Study two was published in the European Journal of Applied Physiology, Nov 22, 2010. The 
purpose of the following study was to evaluate the immunomodulatory effects of short-term 
administration of recombinant human GH (rhGH) in healthy young males. NK cell number, 
activity and phenotype, T cell number, cytokine production of IL-2, IL-4, IL-6, IL-10, TNF-α 
and IFN-γ and CD4+/CD8+ ratio. The study also evaluated the results with IGF-I production 
by RIA. 
3.3 Study Three 
The study three was accepted for publication in the Doping Journal and the aim of this study 
was to evaluate the effects on the gene expression of selected immune genes (IL6, IL6R, 
IL10R, PFR1, NFKB and GZMA) after short-term administration of rhGH.  
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Abstract 
 
Introduction: It has been shown that growth hormone (GH) exerts regulatory effects on 
haemorheology and other metabolic functions. Growth hormone stimulates the production of 
IGF-1 and GH–IGF-I system has profound effects on body fluid status. There is speculation 
that GH has become widely used as a performance enhancing drug among athletes of various 
sports.   The present study evaluated the possible hemorheological effects of short-term 
administration of human recombinant growth hormone (rhGH) in healthy young males. 
Methodology: 30 young healthy males (27 ± 9 years) participated in a 29 day study where 
they were administered either 0.9% sodium chloride or 1mg of human rhGH from day 1 to 
day 7. The participants were randomly assigned into either placebo (C) n=15 or rhGH 
1mg/day (rhGH) group n=15. This study evaluated plasma fibrinogen levels, red blood cell 
(RBC) aggregation and deformability and serum insulin-like growth factor I (IGF-I) level 
between and within the groups along 29 days. Results: There was a significant increase in 
erythrocytes aggregation index post rhGH administration (day 8), in accordance to an 
increase in IGF-I level in serum. 
Key words: rhGH; aggregation, deformability, fibrinogen, IGF-I. 
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1. Introduction 
Human growth hormone (hGH) is considered a pleiotropic hormone that is essential for the 
stimulation of many metabolic processes in cells (Barroso et al., 2008). For the first time in 
the sport’s history during the 2004 Olympic Games in Athens athletes were tested for the 
presence of recombinant human growth hormone (rhGH) in competition. In total, 691 blood 
specimens were tested for rhGH as well as haemoglobin-based oxygen carriers (HBOCs) and 
homologous blood transfusion (BT). All samples analysed for rhGH (397 in total) were 
reported negative as there is not a test for rhGH able to detect it after a short period (24 h) of 
time after administration of the hormone. Recombinant human growth hormone is described 
as the most expensive, most fashionable and least understood of the new athletic drugs (Holt 
and Sonksen, 2008), rhGH alone or in combination with other performance enhancers has 
been considered the prevailing drugs of choice (Holt and Sonksen, 2008).  
The rheological properties of plasma and blood cells are markedly influenced by hormones 
(Brun, 2002). Growth hormone and insulin-like growth factor I (IGF-I) have been 
demonstrated to stimulate erythropoiesis in vitro (Golde et al., 1977) and in animal models 
(Peschle et al., 1972).  
The affects on morphology and filterability of circulating red blood cells (RBCs) between 
GH and the rheologic function of circulating RBC has been suggested by Engstrom and 
colleagues (1990) using hypophysectomised rats (Engstrom et al., 1990). Growth hormone 
treatment (1mg/kg/day continuously infused in female rats during 21 days) was shown to 
normalise RBC deformability and filterability. Importantly comparable, GH has been shown 
to induce erythropoiesis (Brun 2002) as erythrocytes express specific receptors for IGF-I and 
II (Polychronakos et al., 1983). However, whether administration of rhGH has a regulatory 
effect on blood rheology in healthy young males is not known. 
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Furthermore GH is able to increase Total Blood Volume and stimulate erythropoiesis in 
adults with growth hormone deficiency (Christ et al., 1997). Administration of GH (0.036 
U/kg·day) increased mean IGF-I values to within the normal range. GH treatment 
significantly increased RBC number at 3 months with no change in the placebo group (Christ 
et al., 1997).  
Plasma proteins such as fibrinogen concentration promote RBC aggregation being considered 
the most important determinant of the aggregating property of plasma (Rampling 1988) and it 
affects blood viscosity both at high shear rate (primarily relevant for flow in arteries, 
arterioles, and capillaries) and low shear rate (relevant for flow in veins and under stasis) 
(Vayá et al., 2009). 
It can be implied that the delivery of substrate and O2 to muscle can be increased by the 
administration of GH and IGF-I (Luquita et al., 2009), highlighting an interaction between 
GH and haemorheology. However, further studies need to be conducted to assess the effect of 
administration of GH on blood rheology of healthy adults. The aims of the study were to 
evaluate the effects in aggregation, deformability, plasma fibrinogen and IGF-I levels in 
healthy young males due to short duration administration of rhGH. 
2. Material and Methods 
Healthy males (n=30) were randomly assigned into two groups: treatment and placebo.  Daily 
injections of either rhGH (1mg) or placebo (0.9% sodium chloride) were intramuscularly 
administrated for 7 days. Prior to each injection all subjects received a standard breakfast 
(protein shake Body Science, Australia).  Subsequent to the injections, collected blood 
samples from all participants were assessed for aggregation, deformability and plasma 
fibrinogen prior to (day 0), post seven days injection (day 8).  
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Blood samples (50mL) were collected, via venipuncture of an antecubital vein into 
ethylenediaminetetraacetic acid (EDTA), serum separator tubes (SST) and heparin tubes 
(Becton Dickinson, USA).  
2.1 Subjects 
Thirty healthy young males were recruited and randomly divided into two groups. rhGH 
(n=15, 24.5 ± 6.5 y.o.) for the treatment group and Placebo (n=15; 26.1 ± 6.6 y.o.). 
Volunteers were excluded on the basis of the following conditions: (a) regular use of 
therapeutic and/or recreational drugs, (b) contraindications or risk to exercise (recent 
injuries/risk factors for maximal strength testing). Selected subjects were required to read and 
sign an informed consent form prior to the experiment. This study was approved by the Bond 
University Human Research Ethics Committee. 
2.2 Erythrocyte Aggregation  
The Myrenne aggregometer (light-transmission technique) was used to determine erythrocyte 
aggregation by methods previously described (Marossy et al., 2009), where erythrocytes 
aggregation was assessed at ‘M’ (aggregation during stasis after shearing at 600 s-1) and ‘M1’ 
(facilitated aggregation at low shear rate after shearing at 600 s-1). Erythrocyte aggregation 
tests were performed in native blood immediately after collection, haematocrit (HCT) 
adjusted autologous plasma solution as well as in standardised HCT adjusted 3% Dextran-70 
solution at a 40% HCT to account for variation between subjects.  
2.3 Erythrocyte Deformability 
Erythrocyte deformability was determined by methods described by Shin and colleagues 
(2005). Briefly it consists of laser diffractometry in the Ektacytometer (Technicon, France) 
which measures the ellipticity of the diffraction image produced by a laser beam as the red 
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cells elongate under rotational shear. An elongation index is calculated from the light 
intensity along the major and minor axes of the diffraction image. 
2.4 Plasma Fibrinogen 
Plasma fibrinogen concentration was determined quantitatively using the Von Clauss clotting 
method (Clauss, 1957). It measures the rate of fibrinogen to fibrin conversion in diluted 
sample under the influence of excess thrombin (Clauss, 1957).  
2.5 IGF-I serum concentration 
The double antibody radioimmunoassay system (RIA) was applied for quantitative in vitro 
diagnostic measurement of IGF-I in serum by a commercial RIA (IGF-I kit – Bioclone – 
Australia). IGF-I is firstly separated from its binding protein in plasma then, the analyte 
competes with 125I labelled tracer antibody for binding to a constant amount of antibody. A 
second antibody coupled to magnetisable polystyrene particles is used to separate antibody 
bound from free 125I labelled tracer antibody. 
2.6 Statistics 
The statistical analyses were performed using SPSS software, version 17.0. ANOVA was 
applied and the differences were considered statistically significant when p≤0.05. Bonferroni 
was the post hoc test applied. 
3. Results 
Table 1. Subjects characteristics (mean±SD). 
Group N Height (cm) Weight (kg) Age (years) 
Placebo 15 178.9±5.9 83.1±9.1 26.1±6.6 
rhGH 15 178.8±9.5 81.2±17.9 24.5±6.5 
 Haematocrit 
Haematocrit (HCT) was determined using a full blood count from the Coulter Counter (Table 
2). Samples had the HCT adjusted to 40% either by removing or adding autologous plasma.  
Table 2. Haematocrit (%) of groups before being adjusted for aggregation measurement. 
Group HCT_day 0 HCT_day 8 HCT_day 15 HCT_day 22 HCT_day 29 
Placebo 
 
Mean 42.30 41.52 42.98 42.65 41.57 
SEM 0.89 0.66 0.58 0.74 0.87 
rhGH 
 
Mean 42.76 42.48 42.91 42.73 42.59 
SEM 0.93 0.65 0.55 0.61 0.54 
Note: HCT adjusted 3% Dextran-70 solution at 40% HCT 
Erythrocyte aggregation 
Erythrocyte aggregation at indexes “M” and “M1” demonstrated significant difference from 
baseline (week 1) to day 8 (week 2) between groups and within group (rhGH). 
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Figure 4. Erythrocyte Aggregation index at “M1” after adjustment for 40% HCT. 
Fibrinogen 
Initial measurements of fibrinogen were determined for baseline at day 0 and both groups 
showed similar results. Fibrinogen presented no statistical difference between groups at day 8 
after subjects had received 7 days of either 1 mg/day of rhGH or 0.9% sodium chloride 
injections. After a slight increase in plasma fibrinogen mean in the rhGH group (Fig.1) from 
baseline to day 8 (3.10 to 3.61 g/L), results were levelled off at day 15 showing no difference 
between groups compared to baseline (Day 0). 
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* Significant decrease (p≤0.05) in plasma fibrinogen from day 8 to day 22 in the rhGH group. 
Figure 5. Plasma fibrinogen (g/L) measurements from baseline (day 0) to day 29.  
Deformability 
In the rhGH group the deformability was not significantly different from the Placebo group 
along the days of the study (Fig. 6).   
 
Figure 6. Deformability from day 0 to day 29 for Placebo and rhGH groups. 
1.6
2.6
3.6
4.6
Day 0 Day 8 Day 15 Day 22 Day 29
(g
/L
) rhGH
Placebo
0
0.1
0.2
0.3
0.4
0.5
0.6
0.1 1 10 100
P_0
rhGH_0
P_8
GH_8
P_15
rhGH_15
P_22
rhGH_22
P_29
rhGH_29
Sheer Stress (Pa)
* 
E
lo
ng
at
io
n 
In
de
x 
64 
 
 
* Significant difference between day 8 and days 0, 15, 22 and 29 for p≤0.05. 
Figure 7. IGF-1 analysis in plasma per collection day (0 to 29) for groups. 
 
* Significant correlation Pearson p≤0.05. 
Figure 8. Correlation of erythrocytes Native “M” (NM) aggregation index with IGF-I in 
serum from day 0 to day 29 of the study. 
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* Significant correlation Pearson p≤0.01. 
Figure 9. Correlation of erythrocytes Native “M1”aggregation index with IGF-I in serum 
from day 0 to day 29 of the study. 
4. Discussion 
The study aimed to evaluate possible alterations in blood rheology and IGF-I levels in healthy 
young men after short-term (7 days) administration of 1mg of rhGH compared to (C) healthy 
subjects. The results of this study demonstrated that 7 days of rhGH (1mg) administration 
induced significant alterations in the blood rheology as well as in IGF-I concentration in the 
serum of healthy young males.   
Fibrinogen is the major determinant of plasma viscosity and erythrocyte aggregation (Clauss, 
1957). It affects blood viscosity at high shear rate (primarily flow in arteries, arterioles, and 
capillaries) and low shear rate (in veins and under stasis) (Clauss, 1957).  Although plasma 
fibrinogen had an increase of 0.55 g/L from baseline to second week in the rhGH group, it 
was not statistically different from baseline. Perhaps this showed to be enough to induce a 
significant increase in the index of aggregation in the rhGH group from baseline to day 8. 
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Native aggregation (whole blood) of erythrocytes was significantly increased on day 8 in the 
rhGH group, after receiving 7 days of rhGH injections. However, the results for aggregation 
index at day 29 showed a significant decrease compared to day 8 indicating an acute effect of 
the hormone.   
While there are GH receptors in the bone marrow, in vitro experiments using human 
erythroid progenitors have shown that the role of GH in erythropoiesis is probably mediated 
by IGF-I resulting in potential proliferation in erythroid progenitors (Philipps et al., 1988). 
IGF-I in serum increased significantly 24 h after rhGH administration p≤0.01 and remained 
constant for the placebo group. 
The GH–IGF-I axis is a regulator of blood rheology and in physiological conditions such as 
regular training in athletes it has the potential to alter blood rheology factors (Peyreigne et al., 
1998). GH and IGF-I, together with other hormones and growth peptides, modulate the 
formation and functional activation of mature blood cells. GH appears to have multiple direct 
and indirect effects on the human fetal bone marrow compartment by facilitating the 
proliferation and maturation of multilineage progenitor cells (Hanley et al., 2005).  
Significant correlations were established between increase in Native aggregation indexes and 
IGF-I serum for the rhGH group (0.45 and 0.48 for NM p≤ 0.05 and NM1 p≤ 0.001 
respectively). Levelling off on day 15 of the study, IGF-I levels due to rhGH injections 
presented acute effects on blood rheology, mainly on native aggregation. Previously, IGF-I 
had shown to be correlated with blood viscosity in 39 healthy males (elite sportsmen, age 
23.7±0.72 years) on physical training, when in the upper quintile IGF-I levels were associated 
with an increase in erythrocyte aggregation, and increased viscosity of the blood (Monnier et 
al., 2000). 
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Whether the reported increase in erythrocytes aggregation indices and IGF-I in serum can 
lead to any improvement or decrement in sports performance is still to be studied.  
6. Conclusion 
The results from this study indicate 1mg/day of rhGH for seven days may adversely affect 
blood rheology. Whether users may be more liable to higher viscosity of blood highlighting 
potential adverse health effects of the use of rhGH needs investigation.  
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Abstract 
It is reported that in both elite and recreational athletes Growth Hormone (GH) is the most 
commonly used drug aimed at improving sport performance. Aim: The purpose of the 
present study was to evaluate the immunomodulatory effects of short-term administration of 
recombinant human GH (rhGH) in healthy young males. NK cell number, activity and 
phenotype, T cell number, cytokine production of IL-2, IL-4, IL-6, IL-10, TNF-α and IFN-γ 
and CD4+/CD8+ ratio with particular attention to the  possible correlation to IGF-I production 
were investigated. Methodology: 30 healthy young males (27 ± 9 yrs) were randomly 
assigned to either placebo (n = 15) or drug (rhGH) 1mg/day groups (n = 15) with daily 
injection for seven days. IGF-I serum concentration and flow cytometry data were generated 
at baseline (day 0) and days 8, 15, 22 and 29 post injection. Data was analysed using a 
General Linear Model with repeated measures with a Bonferroni correction factor and 
significance set at p≤0.05. Results: The T cell cytokine secretion profile indicated a Th1 - 
Th2 shift. Interestingly, a significant difference (p≤0.05) of IL-10 mean fluorescence is noted 
from day 15 (P= 35.14; ± 19.93, rhGH = 26.63; ± 16.39) to day 22 (P= 61.32; ± 20.41, 
rhGH= 74.99; ± 46.91) and to day 29 (P= 101.98; ± 67.25, rhGH= 107.74; ± 122.58). Serum 
IGF-I concentration (ng/mL) increased significantly (p≤0.01) on day 8 (0.48 ± 0.78) after 
injections compared to baseline (0.31 ± 0.07) as well at day 15 (0.33 ± 0.06), 22 (0.29 ± 0.05) 
and 29 (0.29 ± 0.06). In conclusion, the cytokine secretion spectrum is affected by short-term 
rhGH administration in healthy young males being suggested to have induced CD4+ T 
lymphocytes production of IL-10. 
Key words: Exogenous human growth hormone; Cytokines; Killer cells, natural; Doping in 
sports, insulin-like growth factor I  
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1. Introduction 
Several factors contribute to the reasons why both top level and amateur athletes use banned 
substances and include prospects of increased financial gain, the desire to become famous 
and a raising of social status (Aquino Neto, 2001). Despite the widespread belief that 
administration of growth hormone (GH) will enhance sport performance, there is little 
supportive data to match this belief. Although it is well known that GH induces hepatic IGF-1 
secretion, little is known regarding its biological effects on immune function and effects on 
the sporting performance of healthy individuals. GH has been banned in sports competition 
and training and is classified as a prohibited substance within section S2 (Peptide hormones, 
growth factors and related substances) of the list generated by the world anti-doping agency 
(WADA, 2009). 
Previous studies have shown that GH alters natural killer (NK) cell function. Interestingly, 
NK cells activity has been found to be significantly impaired in GH deficient (GHD) patients 
(Crist, Peake, Mackinnon, Sibbitt, & Kraner, 1987; Sneppen, Mersebach, Ullum, & Feldt-
Rasmussen, 2002). An 18 month randomized, placebo-controlled, double-blinded trial study 
(n=110) showed that both NK cells total number, and subtype NK cells (CD16+) were 
reduced in GHD patients compared to controls. (Sneppen, et al., 2002).  
Peripheral blood NK cells can be subdivided into CD56dim CD16+ and CD56bright CD16-  NK 
cells (Caligiuri, 2008), which denote the normal and low cytotoxic activity respectively. Such 
phenotypic properties are responsible for unique functional attributes that directly impact on 
the human immune response (Cooper et al., 2001; Caligiuri 2008). 
Other cells do express GH and IGF-I receptors and include B lymphocytes, macrophage, T 
lymphocytes and granulocytes precursors (Auernhammer & Strasburger, 1995). In GHD 
 patients suffering from hypopituitarism, they demonstrate immunological impairment 
parameters such as increased basal plasma levels of tumour necrosis factor
and IL-6 by 340% (Serri et al., 1999). Other studies have shown that blood TNF
significantly higher in children with GHD than the controls, and long
rhGH was effective at reducing such levels 
administration of exogenous GH has been shown to improve a variety of immune cell 
functions including B lymphocyte antibody production and responses 
1994), NK activity (Stephenson, Lee, Bailey, Shepherd, & Melling, 1991)
activity (Gaytan, et al., 1994), T lymphocytes and neutrophil functions 
CD4+ T helper lymphocytes have a regulatory overall effect on immunity and orchestrate 
their activity through diverse cytokine secretions or by direct cell
cytotoxic T lymphocytes are effector cells that secrete and respond to cytokines that can 
target infected cells and induce programmed cell death 
immunological activity and response can be mon
that illustrate critical T cell functions (
have shown that GH effects on normal and neoplastic human T cells enhanced proliferation is 
mediated by local increase expression of IGF
Hochberg, 1988; Mercola, Cline, & Golde, 1981; Mosmann & Coffman, 1989)
The CD4+ T lymphocytes demonstrate the production of a large number of cytokines known 
as Type 1 cytokines with IL2 and IFN
activity of Th2 type cells evokes a strong antibody responses and relatively weak cellular 
activity (Cherwinski, Schumacher, Brown, & Mosmann, 1987; Mosmann & Coffman, 1989)
Th2 cells produce cytokines known as Th2 cytokines and include IL4, IL6, IL10 and TNF
As previously mentioned, long
effectively reduces TNF- α level in these patients 
-
(Andiran & Yordam, 2007)
(K
(Fu, et al., 1992)
–cell contact.  The CD8
(Kimata & Yoshida, 1994)
itored by assessing the CD4
Kimata and Yoshida, 1994). Previous 
-I (Geffner, et al., 1990; Merchav, Tatarsky, & 
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Importantly, IL-10 is well known for having essential immunoregulatory functions with direct 
influence on the activity of several leukocytes subsets. Its potent anti-inflammatory 
properties, suppress the expression of inflammatory cytokines such as TNF-α, IL-6 and IL-1 
from activated pro-inflammatory macrophages (Donnelly et al., 1999).  The IL10 induction 
of anti-inflammatory cytokines has not yet been explored in healthy individuals that have 
used rhGH. 
As rhGH is currently used by elite and recreational athletes, it is important to further 
investigate the cellular effects of rhGH on the immune function of healthy males. The 
purposes of this study were therefore, to evaluate and monitor the immunological effects of 
seven days short-term administration of rhGH on: NK cell activity, number, phenotype 
subsets; the T cell numbers (CD4+ and CD8+) and production of cytokines IL2, IL4, IL6, 
IL10, TNF-α and IFN-γ: and finally the CD4+/CD8+ ratio.  
Methods 
Thirty healthy males were randomly assigned to either a treatment (rhGH, n=15, 24.5 ± 6.5 
yrs) or Placebo (P, n=15; 26.1 ± 6.6 yrs) group. Daily injections of either rhGH (1mg) or 
placebo (0.9% sodium chloride) were administered intramuscularly during a period of seven 
days. Prior to each injection all participants received a standard breakfast (protein shake) 
followed by 15 min rest. Blood samples (EDTA and Heparin tubes) were collected via 
puncture of the antecubital vein by a qualified phlebotomist at baseline (day 0) and at days 8, 
15, 22 and 29 after 7 consecutive days of injections. 
All participants were required to read and sign an informed consent form that was approved 
by Bond University Human Research Committee. Exclusion criteria included: (i) regular use 
of therapeutic and/or recreational drugs, (ii) contraindications or risks to exercise (recent 
injuries/risk factors for maximal strength testing).  Sports Medicine Australia pre-exercise 
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screening tool was used to filter out people at high risk for certain exercise related 
complications. The criterion for selection was based on the American College of Sports 
Medicine’s (ACSM) guidelines (2000) for pre-exercise screening and testing. 
Blood Analyses 
The immunological analysis involved the assessment of NK cell numbers, function and 
phenotypes, CD4+/CD8+ numbers and further assessment examined cytokine production by 
Th1 and Th2 cells – (IL-2, IL-4, IL-6, IL-10, tumour necrosis factor (TNF)-α and interferon 
(IFN)-γ). All methods were performed using previously described methods (Marshall-
Gradisnik, et al., 2008).  Whole blood was collected into either heparinised or EDTA blood 
collection tubes and PBMC were isolated from using Ficoll–Hypaque density gradient 
centrifugation (Amersham Pharmacia Biotech AB, Uppsala, Sweden).  
Determination of the lymphocyte phenotypic subsets (CD4+/CD8+) was performed using 
IMK lymphocyte test kit (Becton Dickinson Immunocytometry Systems, California, USA) as 
previously described (Marshall-Gradisnik, et al., 2008). List mode parameters were collected 
for 10,000 cells within the lymphocyte gate and positive staining was calculated based on the 
subsets control specimens. T cells were defined as CD4+CD3+T cells (T suppressor cells), 
CD3+CD8+ T cells (T helper cells), B cells as CD19+B cells, and NK cells as CD3-cells, 
(CD16+and/or CD56+). Flow-cytometry analyses were carried out using a FACSCalibur 
(Becton Dickinson) as described (Mozaffari, et al., 2004). Lymphocytes populations were 
identified by forward and side-scatter analyses. 
The NK lymphocyte cytotoxicity was assessed as previously described (Marshall-Gradisnik, 
et al., 2008). Briefly, PBMCs were isolated from whole blood using ficoll-Hypaque (GE 
Healthcare) through density gradient centrifugation. The NK cells were labelled with 0.4% 
PKH-26 (Sigma, St Louis, MO) and resuspended at a final concentration of 5x106cells/mL. 
75 
 
The target cells, K562 cell line were used at a concentration of 1x105cells/mL.  The K562 
cells were cultured with NK cells in RPMI-1640 culture media (Invitrogen, Carlsbad, CA) for 
4 hours in 37°C incubator with 5% CO2, at a ratio of 25:1. Following incubation, cells were 
stained with Annexin V-FITC conjugated mAB and 7-AAD reagent (BD Pharmingen, San 
Diego, CA) according to the manufacturer’s instructions. Percentage of cell death was 
measured via flow cytometry as previously described (Donnelly et al., 1999).  
Quantification of NK cells phenotype and NK cells were isolated from whole blood 
according to manufacturer’s instructions using RosetteSep Human Natural Killer cell 
Enrichment Cocktail (StemCell Technologies, Vancouver, BC) and Ficoll-Hypaque density 
centrifugation. Samples were then labelled with mAB CD56-FITC (BD Bioscience, San Jose, 
CA) and CD16-PE (BD Bioscience, San Jose, CA) according to manufacturer’s 
specifications and analysed using flow cytometry.  
The Th1 and Th2 profiles were assessed in whole blood samples 10mL of blood were 
collected into lithium heparin tubes from all participants (BD Bioscience) and layered over 
Ficoll-Hypaque for isolation of white blood cells (WBC) following centrifugation at 400g for 
40 minutes and washed twice and resuspended in RPMI-1640 culture medium containing 5% 
foetal bovine serum (FBS). Isolated CD4+T cells were mitogenically stimulated with or 
without 1µg of phytohemagluttinin (PHA). Cells were cultured in a 96 well plate at a 
concentration of 1x106 cells/mL at 370C with 5% CO2 for 72 hours. Supernatants were then 
removed from cells and assessed for Th1, Th2 cytokines using cytometric bead array kit (BD 
Bioscience) as specified by the manufacturer. 
Double antibody radioimmunoassay system (RIA) was applied for quantitative in vitro 
diagnostic measurement of IGF-I within serum using a commercial RIA (IGF-I kit – 
Bioclone – Australia). Briefly, IGF-I was separated from its plasmatic binding protein then, 
76 
 
the analyte competes with 125I labelled tracer antibody for binding to a constant amount of 
antibody. A second antibody coupled to magnetisable polystyrene particles was used to 
separate antibody bound from free 125I labelled tracer antibody as specified by the 
manufacturer. 
Data Analyses 
The statistical analyses were performed using SPSS software (version 17.0). General Linear 
Model with repeated measures was applied and criterion for significant difference was set at 
p≤0.05 with Bonferroni post hoc correction applied. 
Results 
Both groups were not significantly different (p>0.05) in height (P; 178.9 ± 5.9 cm, rhGH; 
178.8 ± 9.5 cm), weight (P; 83.1±9.1 kg, rhGH; 81.2±17.9 kg) or age (P; n=15; 26.1± 6.6 yrs; 
rhGH 1mg/day; n=15; 24.5 ± 6.5 yrs). 
The flow cytometry results revealed no significant differences (p>0.05) between or within 
groups for NK cell numbers, phenotype or NK activity from baseline (day 0) to day 29 
(Table. 1).  
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Table 1.  Natural killer cells absolute numbers (Mean ± SEM), lysis and phenotype in 
MF(AU) from day 0 to day 29 for P (placebo) and rhGH groups. 
 
The T cells number (CD4+ and CD8+), CD4+/CD8+ ratio and cytokyne production by TH1 
and TH2 were also analysed by flow cytometry and showed no significant differences 
between or within groups for CD4+ and CD8+ numbers from Day 0 (P= 3700.08±315.52 
mean fluorescence) or for  CD4+/CD8+ ratio from day 0 (rhGH=3751.00±297.7 and 
P=1.35±0.40; rhGH=1.26±0.43) to Day 29 (P=3765.42±293.5; rhGH=3830.2±149.63 and P= 
1.55±0.47; rhGH=1.28±0.44 mean channel fluorescence).  
The T cell cytokyne production of IL10 increased significantly in rhGH group from day 15 
(P=46.32±44.16; rhGH=30.16±23.09 mean channel fluorescence) to day 22 (P=74.28±36.10; 
rhGH=65.32 ± 35.37 mean channel fluorescence) and remained increased at day 29 (P= 
107.50±60.92; rhGH=57.21±54.57 mean fluorescence) as shown in Figure 2. In contrast, IL2, 
Assay Group Day0 Day8 Day15 Day22 Day29 
NK 
number 
P 669±325.1 587.8±222 611.4±322.8 555.5±348.3 550.7±270.4 
rhGH 560.4±328 492.5±229.7 492.8±190.3 474.79.±160.9 535.2±154 
Nk lysis 
P 35.30±4.57 41.96±6.58 67.80±3.87 31.42±4.76 40.80±6.61 
rhGH 34.85±7.63 33.91±5.97 61.64±3.17 41.18±5.73 44.23±7.23 
Nk 
phenotype 
P  Bright 217.8±162 224.8±67 257±72 197±161 203.3±104 
rhGH 
Bright 
313.8±158 402.3±345 302.1±221 281.3±86 242.1±140 
P Dim 5.606±2011 5.428±1091 5.788±866 4.391±2653 4.860±1429 
rhGH 
Dim 
5.687±1245 5.309±1827 5.072±2032 4.937±1175 5.210±1034 
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IL4, IL6, TNF-α and IFN-γ showed no significant (p≥0.05) difference from baseline to day 
29 in both groups (Table 2.).  
Table 2. T cell cytokine production from baseline to day 29 for placebo (P) and rhGH 
groups in MF(AU). 
 
A significant difference (p≤0.01) was found in serum IGF-I concentration in the rhGH group 
at day 8 (0.49 nmol/mL) compared to baseline (0.32 nmol/mL) (Figure 1.) while no other 
time point was significant for this group. There was no significant difference in serum IGF-I 
for the control group from baseline to day 29. 
Assay Group Day0 Day8 Day15 Day22 Day29 
IL2 
P 427.77±195.76 501.30±201.52 374.60±144.90 401.76±192.02 519.94±181.65 
rhGH 517.02±115.57 345.29±172.65 355.30±202.78 464.27±217.19 499.13±153.21 
IL4 
P 8.29±3.22 7.47±2.36 8.93±3.79 8.05±1.76 12.42±5.97 
rhGH 10.08±3.83 7.08±2.20 8.67±6.39 8.60±5.65 13.69±9.67 
IL6 
P 4796±1608 4193±1814 2635±1666 2188±1733 3730±1941 
rhGH 5289±1862 3243±1512 3122±1478 3670±2025 3584±1651 
TNF-α 
P 156.70±60.78 138.33±37.80 135.90±96.87 102.65±42.18 125.73±52.39 
rhGH 141.81±46.94 180.33±73.80 131.64±59.42 152.22±72.23 131.02±54.61 
IFN-γ P 481.73±175.98 373.19±213.82 368.45±250.25 338.02±150.64 430.83±254.47 
rhGH 453.15±258.86 382.38±236.18 382.77±155.94 294.37±161.92 296.51±161.27 
 * S
Figure 1. I
              * Sig
Figure 2. I
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Discussion 
The aims of this study were to evaluate in young males, the immunomodulatory effects of 
short-term administration of rhGH on NK cell number, activity and phenotype, T cell 
cytokine production of IL2, IL4, IL6, IL10, TNF-α and IFN-γ and CD4+/CD8+ ratio in human 
PBMCs, with particular attention to the possible correlation to IGF-I production.  
The present study indicated no changes in NK cell count, phenotype or activity in either the 
experimental or placebo group. In contrast, in experiments with 24 month old Wistar rats, 
rhGH replacement therapy (2 mg/kg daily for 10 weeks) significantly improved several 
lymphocyte functions such as NK cell activity (Baeza, et al., 2008). Interestingly, a previous 
study confirmed that both total NK cell count and particularly CD16+ NK cell subtype were 
reduced in GHD patients compared to controls (Sneppen et al., 2002). However, the studies 
presenting significant results on NK cell were performed for a period of at least ten weeks, 
suggesting the time course of GH replacement may be a key factor.  
In addition, serum IGF-I level significantly increased on day 8 within the rhGH group and 
along with the high numbers of IGF-I receptors  known to be on NK cells (Kooijman, et al., 
1992), it was predicted that NK cells activity would be altered after short-term administration 
of rhGH. However, rhGH induce IGF-I release did not alter NK cells activity nor their 
number or phenotype in our study. Serum IGF-I concentration in the rhGH group and 
Placebo group showed only a weak correlation with NK cell activity. 
The current results indicate that IGF-I has the potential to exert anti-inflammatory actions 
through stimulation of IL10 production in CD4+ T lymphocytes. The IL-10 cells may inhibit 
the production of Th1 cytokines (Moore, de Waal Malefyt, Coffman, & O'Garra, 2001) 
leading to the prevalence of Th2 cells. IGF-I may induce a shift from the production of Th1 
to Th2 cytokines, leading to a diminution of cellular immune responses and a stimulation of 
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antibody-mediated responses. It would appear that rhGH for short-period of time may exert 
its stimulation effects of Th2 through IL 10 release in healthy population with possible anti-
inflammatory action.    
The rhGH therapy is a recognised procedure for enhancing immune function in GH deficient 
populations (Crist et al., 1987; Sneppen et al., 2002; Serri et al., 1999; Andiran and Yordam, 
2007), and our data suggest that a dose of 1mg/day for seven days may potentiate immune 
function of healthy young males through the significant increase in the release of IL10 by 
CD4+ T lymphocytes.  
Conclusion 
The rhGH has been used by athletes with the intention of improvement of performance. 
Moreover, there is no evidence of its effect on the immune function. In this paper, it was 
shown that rhGH stimulated IL10 secretion by CD4+ T cells in healthy young males.  
Although the lymphocyte numbers between both groups were not significantly different from 
baseline to day 29, cytokine production showed a non significant decrease followed by a 
significant increase from day 15 to day 22 and 29 and from day 22 to day 29.  In conclusion, 
cytokine release can be affected by short-term rhGH administration in healthy young males 
suggesting that rhGH may act on CD4+T lymphocytes by increasing IL10 production and 
may then be a key component in T cell activation.  
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Abstract 
Introduction: Limited studies have provided little evidence for the effects of exogenous 
recombinant human growth hormone (rhGH) on the immune response at and through the 
gene level. The aim of this study was to evaluate the effects on the gene expression of 
Interleukin 6 (IL6), Interleukin 6 receptor (IL6R), Interleukin 10 receptor (IL10R), Perforin 
(PFR1), Nuclear Factor Kappa B (NFKB) and Granzyme A (GZMA), genes related to 
immune function and regulation, after short-term administration of rhGH. Methodology: 
Thirty males (age: 27 ± 9 yrs) were randomly assigned to either placebo (P) or rhGH 
(1mg/day for seven days) groups. Gene expression was evaluated by microarray and 
confirmed by quantitative real time PCR (q-RT PCR) analysis for both groups following P 
and rhGH groups pooling of cDNA. Data was generated at baseline (day 0) and days 8, 15, 
22 and 29 post injections. Results: The ratio of expression at each time point post baseline 
was normalised against baseline expression values. On day 8 all evaluated genes except IL6 
presented an up-regulation in fold of expression in the ratio against baseline in the rhGH 
group in contrast with the placebo group. From day 8 to day 29 all the evaluated genes apart 
from IL6 remained up-regulated in relation to baseline in the rhGH group. Conclusion: 
Short-term administration of rhGH was effective in elevating the gene expression of IL10R, 
IL6R, NFkB, GZMA and PFR1 suggesting the activation of anti-inflammatory responses. 
Key Words: Gene expression, recombinant human growth hormone, immune function, q-RT 
PCR. 
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Introduction 
A number of neuroendocrine hormones produced in the anterior pituitary, for example 
growth hormone (GH), have particularly prominent effects on immunity which have been 
shown to exert stimulatory property on both human and murine T cells in vitro, including 
enhancement of T cell proliferation and functional antigen responses [1, 2]. Human GH 
regulates various components of the immune system, such as lymphopoiesis [3] and 
immunological cytokine mechanisms [4].  
The physiologic functions of GH are mediated by two different but complementary 
mechanisms: it directly activates target organs via specific GH receptors while indirectly its 
effects are mediated through insulin like growth factor 1 (IGF-I). Insulin like growth factor 1 
and its receptor (IGF-IR) provide a potent proliferative signalling system that stimulates 
growth in many different cell types and blocks apoptosis. In vivo, IGF-1 acts as an 
intermediate of many growth hormone responses [5].  
The anabolic actions of human GH have made it attractive as a potential ergogenic agent for 
athletes although there is a lack of evidence to support increased performance in sports after 
rhGH use. However, it is highly plausible and likely, that elite athletes are using rhGH in 
dosages ranging from approximately 15 to 180µg/kg per day, which would be significantly 
higher than dosages used in most experimental studies [6].  
In vivo studies have shown that GH administration increases natural killer cell (NK) activity 
[7]. Furthermore, GH increases cytokine transcript levels in lymphoid cells in vitro [8] and 
IGF-I generated, in response to GH, can act on immune cells giving rise to a secondary 
response [3]. 
Several authors [9-11] have recently explored the use of peripheral blood mononuclear cells 
(PBMCs) as a source of material for gene expression analyses in humans. This current study 
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used PBMCs to evaluate the effects of rhGH administration in the gene expression of selected 
genes with influence on the immune function.  
Growth hormone signals through the GH receptor (GHR), which couples to the cytoplasmic 
tyrosine kinase, Janus kinase 2 (JAK2) [12], and GH has been shown to activate STATs 1, 3, 
and 5 [13]. The STAT proteins play a prominent role in the GH-induced regulation of gene 
transcription [14]. RT-PCR is a highly sensitive and versatile technique for amplification and 
quantification of RNA [15]. 
The aim of this study was therefore to determine if selected genes related to the immune 
function and regulation (Interleukin-6 (IL6), Interleukin-6 receptor (IL6R), Interleukin-10 
receptor (IL10R), Perforin-1 (PFR1), nuclear factor κB (NFκB) and Granzyme A (GZMA)), 
important to the inflammatory and anti-inflammatory responses are influenced by short-term 
administration of rhGH.  
Methods 
Thirty healthy young males were recruited and randomly divided into two groups: rhGH 
(n=15, 24.5 ± 6.5 yr) for the treatment group and placebo (n=15; 26.1 ± 6.6 yr). Volunteers 
were excluded on the basis of regular use of therapeutic and/or recreational drugs and 
contraindications or risk to exercise (recent injuries/risk factors for maximal strength testing). 
Daily injections of either rhGH (1mg Genotropin “Miniquick”, Pfizer, Sydney) or placebo 
(0.9% sodium chloride) were intramuscularly administrated for seven days. Prior to each 
injection all subjects received a standard breakfast (protein shake, Body Science, Australia).  
Subsequent to the injections, collected blood samples from all participants were assessed for 
gene expression at the following times: prior to (day 0) injection and seven (day 8), 15 (day 
15), 22 (day 22) and 29 (day 29) days after the injection. Subjects were required to read and 
sign an informed consent form prior to the experiment and the study was approved by Bond 
University Human Research Ethics Committee. 
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Blood collection & white blood cell extraction 
 
Blood samples from subjects were collected into 4mL EDTA blood tubes. Peripheral blood 
mononuclear cells extraction was carried out in Ficoll-paque and the protocol consisted of the 
following: within a 14 mL Falcon tube, 4 mL GIbco PBS, pH 7.4 sterile was added to 4 mL 
of fresh blood; Tubes were then inverted 3 times and  8 mL of diluted blood was layered over 
4 mL of Ficoll-paque. Post centrifugation  at 900 RCF for 20 min/room temperature, plasma 
was removed gently (stored at -80C°) and WBC were collected using with a 1000µL pipette 
(filter tipped) and spun down  at 4C°/4000 RCF/10 min and rinsed in PBS, pH 7.4 and finally 
stored at -80C° for further processing. 
Extraction of total RNA 
 
Total RNA was extracted from PBMC stabilized in RNA tubes, amplified, and hybridized to 
Illumina HumanRef-8v2 bead chips each representing >24,000 sequences representing NCBI 
RefSeq genes.  
The TRizol® Plus RNA purification kit (Invitrogen Australia Pty Limited) was used to 
isolate total RNA. Briefly, sample tubes were removed from a -80°C freezer and placed at 
room temperature with TRizol® Plus RNA purification kit (Invitrogen). Lysis of cells was 
performed by passage through pipette tips several times and incubated for 5 min at room 
temperature to allow complete dissociation of nucleoprotein complexes. 0.2 mL chloroform 
was then added and gently mixed by hand for 15 sec. Following 3 min incubation (room 
temperature), the sample was centrifuged at 12,000 x g for 15 min at 4°C. A colourless upper 
phase containing the RNA was collected gently and transferred into a new tube containing an 
equal volume of 70% ethanol. Samples were vortexed for 30 sec and placed above RNA Spin 
cartridge. Binding of RNA, washing steps and elution series were undertaken following 
manufacturer’s instructions. The RNA was eluted into 100 µL of pure water and quality 
control was established on RNA samples. Assessment of both RNA concentration and purity 
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was executed with the NanoDrop 1000 Spectrophotometer. RNA quality was assessed by 
taking into account ratio measurements for both 260/280 and 260/280 ratios. 
Microarray and cDNA synthesis: 
 
In this study, we analysed gene expression profiles of individuals prior to injection (baseline) 
and following a sequence of doses of 1mg recombinant GH administered intravenously daily 
for seven days. 0.9% sodium chloride was administered daily to the Placebo group for seven 
days. Blood samples were collected at baseline and in weekly intervals post injection (day 8 – 
time point 1) and following times (day 15, day 22 and day 29 corresponding to time points 2, 
3 and 4 respectively). RNA extraction from whole blood PBMCs was followed by microarray 
experiments using the Illumina chip platforms. Cluster analysis in this study revealed a 
collection of genes with altered expression. 
The synthesis of cDNA was undertaken using the SuperScriptTM III First-Strand Synthesis 
SuperMix for qRT-PCR kit (Invitrogen Australia Pty Limited). Briefly the methods consisted 
of making a reaction mix [10µL of 2X RT Reaction Mix; 2µL of Reverse Transcriptase 
Enzyme Mix; 8µL of Eluted RNA (2 µg)], observing incubation a 10 min at 25°C, followed 
by a second incubation at 50°C for 30 min. The reaction was stopped by bringing the reaction 
at 85°C for 5 minutes. The overall cDNA was stored at -20°C. 
Following collection, cDNA from control samples was pooled at equal amounts and cDNA 
from samples were pooled in the same manner. 4 µL of diluted cDNA (1 in 100 dilutions) 
was used as templates. Sybr mix including Taq polymerase (iQTM SYBR® Green Supermix; 
BIO-RAD - USA) as well as forward and reverse primers (0.5 µM each; see Table 1) 
(Geneworks, Australia) were added to the cDNA for a final volume of 25 µL. Primers were 
previously designed using primer 3 (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi).  
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Table 1. PCR primers designed for detecting specific genes related to the immune function. 
All primer sequences are presented in 5' to 3' orientation.  
 
Gene name 
Genes 
Unigene 
accession 
number 
Forward Reverse 
Granzyme A  
GZMA 
Hs.90708 
CTGTGATTGGAATGAATATGGTTTGT CAGAATCTCCATTGCACGAGTCT 
Interleukin 6 
receptor IL6R 
Hs.709210 
CACGACTCTGGAAACTATTCATGCTA GGGAACATCCACCAGCAAGT 
Interleukin 6 
IL6 
Hs.654458                                                                                                                    
AAGCAAGTGGGATCACCTATGAA GCAATGTCTTCCACACGAGTTG 
Interleukin 10 
receptor IL10R 
Hs.504035 
TCAGTCACTTCCGAGAGTATGAGATT CTTTCTTGTGTGTGAACGTGAAGTTT 
Perforin 1  
PFR1 
Hs.2200 
CCGCTTCTACAGTTTCCA GTAGTTGGAGATAAGCCTGAG 
Nuclear Factor 
Kappa B NFKB 
Hs.618430 
GGAAGTACAGGTCCAGGGTATAGCT CATGCTTCATCCCAGCATTAGA 
Ribosomal RNA 
18s 18s 
 
TTCGAGGCCCTGTAATTGGA GCAGCAACTTTAATATACGCTATTGG 
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Detection of PCR product in real time was performed using the Corbett Research Rotor-Gene 
3000. The PCR volumes were placed in individual Corbett 0.1 mL strip tubes on -20°C pre-
cool metal tube carriers with this order: cDNA and PCR mix. Tubes were closed off and 
manually handled to allow the whole PCR solution to be at the bottom of the tube. The 
following cycling conditions were used and entered in the Rotor Gene software (Cycle 1, 
94oC 4 minutes (x1), Cycle 2, 94oC 30 s, 59oC 1 min, 72oC 30 sec (x45)). A post-PCR 
amplification protocol was preset before the run to obtain melt curve representations 
(ramping from 50 to 99°C with 1°C ramping every 5 seconds).  
Data Analysis  
cDNA was synthesised from RNA extracted from human peripheral blood mononuclear cells. 
18s was used as an internal standard house keeping that reflects accurately mRNA expression 
levels in PBMCs [16].  Following q-RT PCR analysis, quantification cycle (Cq) values from 
triplicates were collected at linearity and used to calculate the 18S rRNA corrected Cq (or 
∆Cq) for each gene. Triplicate repeat ∆Cq were assigned with ± SE determinations and were 
then used to calculate the mean corrected difference in Cq for placebo and rhGH (or ∆∆Cq). 
The extent of the response was determined by 2-mean (∆∆Cq) (formula which indicates the 
copy number) while a negative value suggests repression of receptor expression, so the 
relative degree of response is calculated by 2-mean (∆∆Cq). The absolute fold change is used 
to denote changes in expression; i.e. a 2-fold increase is equivalent to a doubling of 
expression. cDNA pools of placebo and rhGH samples were used as PCR templates for RT 
PCR experiments to determine relative degree of responses. Our placebo pooling approach, 
with equivalent power, has been previously published in the literature [17, 18]. The mean 
∆Cq value was calculated for both the gene and the internal control. Cq values were 
determined using a threshold line that was set at the exponential phase of all PCR runs and 
therefore calculated for optimum PCR efficiency. All ∆Cqs were then consequently used to 
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calculate 2-∆∆Cq which represents the relative expression levels and allows comparison 
between baseline and time-points. Each RT-PCR was run in triplicate with standard deviation 
less than 0.2. 
Results 
The efficiency of all PCR ranged from 90 to110% meaning doubling of the amplicon at each 
cycle (PCR slopes ranging from -3.1 to -3.6). Therefore the basis 2 is expected and does not 
mirror the real PCR efficiency. The q-RT PCR results indicate rhGH and placebo groups 
presented similar expression for the evaluated genes at baseline. On day 8, all of the 
evaluated genes other than IL6 presented an up-regulation in the ratio against baseline in the 
rhGH group (see Table 2).  
Table 2. Normalised ratios of expression in immune selected genes on day 8, day 15, day 22 
and day 29 relative to the baseline expression of rhGH group compared to Placebo group. 
The relative degree of response (expressed as ratios) was calculated by 2-mean (∆∆Cq) and 
denote changes in gene expression. 
 
Genes Day 8 Day 15 Day 22 Day 29 
NFκB 1.18 4.44 2.77 2.33 
IL6 0.52 0.58 0.59 0.17 
PFR 2.18 2.11 2.14 3.22 
IL10R 2.27 3.68 3.19 4.57 
IL6R 1.77 2.41 1.57 1.8 
GZMA 2.16 4.96 2.11 2.28 
 
Interestingly, on day 15 with the exception of IL6 (0.50 fold), all evaluated genes in the rhGH 
group presented an up-regulation above two fold compared to the placebo group; IL6R – 
2.41, PFR1 – 2.11, IL10R – 3.68, NFκB – 4.44, GZMA - 4.96 fold. 
Although NFκB had a significant drop from day 15 (4.44 fold) to day 22 (2.77 fold), its 
expression remained up-regulated in the rhGH group compared to placebo in relation to 
baseline. PFR1 presented very similar results from day 15 to day 22 with an up-regulation of 
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2.14 fold in the rhGH group compared to the placebo group. A significant decrease was 
shown for genes GZMA and IL6R from day 15 to day 22 (4.96 to 2.11 fold and 2.41 to 1.57 
fold respectively). Interestingly, IL10R presented a non-significant drop from day 15 (3.68 
fold) to day 22 (3.19 fold) following a 4.57 fold increase in up-regulation on day 29 in the 
rhGH group compared to the placebo group in relation to baseline.  
On day 29 GZMA fold expression increased compared to day 22 in the rhGH group, 
remaining up-regulated (2.28 fold) compared to the placebo group. The PRF1 on rhGH group 
reported a significant increase in its expression on day 29 (3.22 fold) compared to day 22 and 
compared to the expression in the placebo group relative to baseline.   
There was no significant difference in the IL6 gene expression between or within groups from 
day 0 to day 29 of the study (Table 2). 
Discussion 
Our study shows that short-term administration of rhGH has an effect on the pro- and anti-
inflammatory gene expression regulation by significantly increasing the expression of IL10R, 
NFkB, GZMA and PFR1.   
The granzyme A and PFR1 presented a similar pattern of up-regulation associated to NFκB 
up-regulation, once more confirming a profile of increased anti-inflammatory responses in 
the rhGH group compared to placebo. A previous study [19] evaluated the effects of exercise 
(30 min of constant work rate cycle ergometry (80% peak O2 uptake)) on the gene 
expression, measured using microarray analysis. The GZMA gene expression reported a 2.0 
fold increase from before to immediately after the exercise bout. However, from the end of 
exercise to after 60 minutes of recovery a down-regulation to -2.97 fold change was 
observed. After 60 minutes into recovery, samples showed down-regulated compared to 
before exercise samples as well. According to our results, rhGH increased anti-inflammatory 
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activation through GZMA, PRF1 and NFkB mRNA up-regulation in healthy young males, 
suggesting an advantage to athletes and their stressed immune system.      
As an effect of rhGH administration the pro-inflammatory genes such as IL6 would be 
inhibited with the NFκB, GZMA, PRF1, IL10R gene expression up-regulated. Miles and col. 
[20] evaluated the perforin gene expression using quantitative RT–PCR from moderately 
trained runners (males from 18 to 40 years old) and compared it to controls before exercise, 
immediately after (0h), 1.5, 5, and 24 h following a 60 minutes run at 80% of VO2 peak. The 
exercise bout decreased the perforin gene expression in the runners group from before to after 
exercise and this decrease was maintained over 24 h. Once again the effects of rhGH 
administration suggest a possible benefit to athletes by up-regulating NFκB, GZMA, PRF1 
mRNA. 
In our study no difference in the IL6 gene expression was noticed between or within groups 
from day 0 to day 29 of the study (Figure 1).  
Figure 1. qRT PCR (top) and melt curve analysis (bottom) results of IL6R gene and 18s gene 
as the keeping house gene. 
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In contrast, IL6R showed increased expression from day 0 to day 29 with little variation along 
the evaluated days.  
Growth hormone therapy over a period of 12 weeks in a randomized crossover comparison 
was previously shown [21] to mediate in the various stages of inflammatory processes in 
patients with idiopathic dilated cardiomyopathy by significantly reducing (p≤0.04) pro-
inflammatory cytokines such as IL6, as well as significantly increasing the ratio IL10/IL6.  
In athletes, the effects of ultra distance (245 km) run considerably increased plasma IL-6 
levels by 8000-fold (7781.0 ± 8317.3 pg/ml) immediately after (within 15 minutes) the end of 
the race, returning to baseline level 48 hrs after the race (0.7 ± 0.5 pg/ml) [22]. 
Interleukin 6 transmits its biological signal through IL6 receptor, an IL6 specific binding 
molecule. Although IL6R mRNA increased in the rhGH group after administration of rhGH, 
IL6 presented unaltered expression. The ligand of IL10R, IL10 has potent anti-inflammatory 
properties inducing the repression of the expression of inflammatory cytokines such as IL6 
by activated macrophages [23]. In our study the up-regulation of IL10R above 2 fold with 
increases along the evaluated days until the end of the study suggests an effect on the 
inhibition of IL6 along the evaluated days. The regulation of IL6 also depends on the protein 
transcription factor NFκB which in our study showed a 4.44 fold increase in its expression 
(See Figure 2).  
Figure 2. Selected genes expression of rhGH group compared to Placebo group from day 0 to 
day 29 of the study in relation to baseline. 
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According to some authors [24] NFκB has a role in the recovery from exercise which is the 
induction of pro- inflammatory genes to facilitate post-exercise regenerative responses in 
damaged tissue. 
This could indicate that beside the unaltered expression of IL6, up-regulation of IL6R could 
potentially trigger more intracellular cascades, including NFκB activation.  
As described by Schottelius and col. [25], in the nucleus NFκB binds to target DNA elements 
and regulates the transcription of genes involved in immune and inflammatory responses.  
The NFκB transcription pathway was shown previously to be a key regulator of IL6 
cytokines [26, 27]. The NFκB has been cited to coordinate the activation of several genes in 
response to pathogens and pro-inflammatory cytokines that are considered crucial in the 
activation of acute as well as chronic inflammatory diseases [25].  
Both receptor genes evaluated in our study, IL6R and IL10R, presented a consistent increase 
in their expression following the rhGH administration, and as previously reported by Lai and 
col. [28] IL10R is highly effective in recruiting the signalling pathways of IL6 cytokine 
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receptors and mediating the immunosuppressive signal of IL10, and thus it inhibits the 
synthesis of pro-inflammatory cytokines. 
In a recent study that applied flow cytometric analysis, Ramos et al. [29], demonstrated a 
time effect of exogenous rhGH on the IL10 production by T helper cells. In this study, IL10 
was shown to be increased in the rhGH group compared to the placebo group 16 days after 
the last day of 1mg of exogenous rhGH. The anti-inflammatory action of IL10 in T cells of 
healthy young males may enhance the cascade activation mediated by IL10R.  
In conclusion, short-term administration of rhGH was effective in up-regulating the gene 
expression of IL10R, IL6R, NFkB, GZMA and PFR1, genes normally affected by exercise 
and important for the immune function regulation suggesting the activation of anti-
inflammatory responses by rhGH.   
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4.0 Discussion 
This is the first study to administer rhGH to healthy young males aiming to evaluate the 
possible effects on their blood rheology, immune system and gene expression. The variables 
chosen are fundamental influences on sports performance as well as important indicators of 
health status. We demonstrated that 7 days of rhGH (1mg) administration in healthy young 
males induced significant alterations in the blood rheology, specifically an increase in the 
native aggregation of RBC. We have also shown that rhGH may perhaps stimulate a chronic 
IL10 secretion by CD4+ T cells, while T lymphocyte numbers and percentage remained the 
same throughout the study. We have demonstrated up-regulation of mRNA expression of 
IL10R, IL6R, NFκB, PFR1 and GZMA genes. 
4.1 Blood rheology aspects 
Alterations in blood rheology, especially increased erythrocyte aggregation, play an 
important role in the development of arterial and venous thrombotic lesions (Demiroglu et al., 
1998). Erythrocyte aggregation is one of the important hemorheological determinants that 
may create problems at the level of microcirculation (Puniyani et al., 1991). It is stated that 
erythrocyte aggregation has a direct effect on the formation of thrombi at low shear 
conditions (Stoltz and Donner, 1987). However, the results for the native aggregation index 
showed only an effect immediately following administration of rhGH but not on days 15, 22 
or 29 of the study.   
Although aggregation of erythrocytes was immediately increased in our study, plasma 
fibrinogen was unaltered from day 0 to day 29 in both groups suggesting that rhGH has no 
influence on fibrinogen. Additionally, fibrinogen cannot be considered a factor in the 
observed increase of erythrocyte aggregation.  Fibrinogen was previously demonstrated by 
Miljic and colleagues (2006) to be unaltered in adults with growth hormone deficiency 
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(GHD), remaining constant after daily GH replacement for 12 months. However, Jeejeebhoy 
al., 1970 in a landmark study, administered bovine growth hormone to rats and observed 
within a few hours a significant increase in the synthesis of fibrinogen. Perhaps the 
methodological differences within doses, collection times and samples between studies lead 
to the different results.The deformability of erythrocytes remained the same within and 
between groups from the beginning until the end of our study which indicates preservation of 
the membrane of the red blood cell after rhGH administration.  
The full blood count indices such as total red blood cells, hemoglobin, hematocrit, mean 
corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), mean corpuscular 
hemoglobin concentration (MCHC), red blood cell distribution width (RDW), platelets and 
platelets mean volume (PMV) showed no difference between groups before or after 
administration of rhGH. Peyreigne et al., (1999) evaluated the main blood rheology 
parameters in adults with growth hormone deficiency (GHD). They found no difference in 
the blood rheology between controls, matched by gender, age and body mass index, and 
GHD patients. However, Christ and colleagues (1997) reported that GH treatment in GHD 
adults (0.036 U/kg.day for three months) stimulated erythropoiesis similarly to the study by 
Kotzmann and colleagues (1996), who showed that after 24 months of treatment with GH to 
GH deficient adults there was a marked effect on erythroid and myeloid progenitor precursor 
cells.  
The increase in the native aggregation of erythrocytes in the rhGH group might affect blood 
viscosity both at high shear rate (primarily relevant for flow in arteries, arterioles, and 
capillaries) and low shear rate (relevant for flow in veins and under stasis) (Vaya et al., 
2009), in low-flow conditions, and may contribute to circulatory disorders and, perhaps in the 
microcirculation, to the occlusions of micro vessels (Luquita et al., 2009). According to 
Marossy and colleagues (2009) the main functions of blood are the transport and delivery of 
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oxygen and nutrients, removal of carbon dioxide and waste products of metabolism provided 
by circulation of the blood. Therefore, based upon our results, we might expect the 
administration of rhGH to healthy young males may lead to an acute detrimental effect on the 
supply of nutrients and O2 for the muscle tissue of athletes in high energy demand 
performance.  
Insulin Growth Factor-I (IGF-I) in serum increased significantly 24 hours after rhGH 
administration (p≤0.001) and remained unaltered in the placebo group, reflecting a very 
similar profile of the aggregation. This suggests that IGF-I has a role in the native 
aggregation of the RBC. The growth hormone–insulin growth factor-I axis is a regulator of 
blood rheology and in physiological conditions such as regular training in athletes it has the 
potential to alter blood rheology factors (Peyreigne et al., 1998).  
4.2 Immune function and regulation 
In the white blood cells (WBC) the ratio of CD4+/CD8+ T lymphocytes remained unaltered 
from baseline to 29 days after rhGH administration. Ramel and colleagues (2003) 
showed CD4+/CD8+ ratio to be decreased during submaximal resistance exercise at 75% of 
their 1 RM (repetition maximum) and increased during recovery. The resistance-trained 
participants tended to have lower T-helper cell counts before, during and immediately 
after exercise and a lower CD4+/CD8+ ratio during recovery than the non-resistance-trained 
participants. Some authors consider the lower CD4+/CD8+ ratio to contribute to the immune 
susceptibility of athletes after strenuous exercise, commonly performed by athletes while 
training or competing.  
The T helper lymphocyte CD4+ was also evaluated in our study as per activation (cytokine 
production), more specifically the production of cytokines such as, Interleukins 2, 4, 6 and 
10, Interferon-γ and Tumour necrosis factor-α. With the exception of IL10, there was no 
103 
 
significant difference between or within groups from baseline to day 29. As shown in Study 
Two the late response of IL10 indicates a possible shift from Th1 to Th2 demonstrating an 
adaptive process by the immune system in an attempt to down regulate atypical inflammatory 
Th1 immune responses. Importantly, IL10 is well known for having essential 
immunoregulatory functions on the activity of immune cells with potent anti-inflammatory 
properties and suppresses the expression of inflammatory cytokines such as TNF-α, IL6 and 
IL1 from activated pro-inflammatory macrophages (Donnelly et al., 1999).   
As previously reported in athletes, ultra distance (245 km) runs considerably increase plasma 
IL6 levels by 8000-fold (7781.0 ± 8317.3 pg/ml) immediately after (within 15 minutes) the 
end of the race, returning to baseline level only 48 hrs after the race (0.7 ± 0.5 pg/ml) 
(Margeli et al., 2005). Therefore GH might aid to balance the pro-inflammatory/anti-
inflammatory system.  
Growth hormone therapy over a period of 12 weeks was previously shown (Adamopoulos, 
2003) in a randomized crossover comparison to mediate in the various stages of 
inflammatory processes in patients with idiopathic dilated cardiomyopathy. It was shown to 
significantly reduce (p≤0.04) pro-inflammatory cytokines such as IL6, as well as significantly 
increasing the ratio IL10/IL6. Similar results were shown in our study since IL10 
significantly increased and IL6 remained the same in healthy young males. It might be seen 
as an advantage for athletes to decrease the pro-inflammatory responses to exercise due to 
rhGH administration. 
In study two, there was no significant effect of rhGH on NK cell count, phenotype or activity. 
In contrast, Crist and colleagues (1987) found a positive relationship between IGF-I levels 
and the cytotoxic activity of NK cells and an increase in NK activity after exogenous GH 
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treatment in women with an impairment in GH secretion. In this case, the contradictory 
results are explained by the difference between impairment or normality of the GH secretion.   
A later study confirmed that both total NK cell count and particularly CD16+ NK cell subtype 
were reduced in GHD patients compared to controls (Sneppen et al., 2002). However, the 
studies that show significant results on NK cells after GH administration were performed 
over a period of at least ten weeks, suggesting the time course of GH replacement may be a 
key factor. Furthermore, improved lymphocyte functions such as NK cell activity was 
presented in GHD populations. This has not been confirmed in our study with young healthy 
non-GHD subjects. Perhaps the effects of rhGH on NK cells are regulatory and not pertinent 
in healthy population. A previous study with non-syndromic short children revealed GH 
receptor expression on immune cells (T, B and natural killer cells expressing CD2+) was 
inversely related to the linear growth expression and the body mass index of subjects (Valerio 
et al., 1997).  
4.3 Gene expression outcome 
The late response of IL10 cytokine production (day 29) might be related to the concurrent 
IL10R mRNA profile expression. On day 29, IL10R expression presented the highest 
measure of a 4.57 fold increase in up-regulation in the rhGH group compared to the placebo 
group from baseline, as reported in Study Three. Although mRNA expression is not a 
measure of protein expression, in our results it may be indicative of it. The IL10R mediates 
IL10 activity, which acts mainly as anti-inflammatory or by managing inflammatory 
response, which is frequently seen in athletes during training or competition seasons.  
The granzime A (GZMA) and perforin 1 (PFR1) presented a similar pattern of up-regulation 
associated to NFκB up-regulation, once more confirming a profile of increased anti-
inflammatory responses in the rhGH group compared to placebo. A previous study (Connoll 
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et al., 2004) evaluated the effects of exercise (30 min of constant work rate cycle ergometry 
at 80% peak O2 uptake) on the gene expression, measured via microarray. The GZMA gene 
expression reported a 2.0 fold increase from baseline to immediately after the exercise bout. 
However, from the end of exercise to 60 minutes post recovery a down-regulation to -2.97 
fold change was observed. After 60 minutes into recovery, samples were down-regulated 
compared to the samples before exercise. This is considered a moment of risk for the athlete 
because of the low immune cell numbers and activity, referred to as the “open window 
theory” (Nieman, 2000).  
According to our results, rhGH increases anti-inflammatory activation through GZMA, PRF1 
and NFkB mRNA up-regulation in healthy young males. This suggests an advantage to 
athletes since being engaged in intensive periods of endurance training appears to make them 
more susceptible to minor infections (Gleeson, 2007). 
A recent study showed that acute exercise activates the NFkB signalling pathway in rat 
skeletal muscle which leads to increased expression of enzymes involved in antioxidant 
defence (inducible nitric oxide synthase, endothelial nitric oxide synthase and mitochondrial 
Mn superoxide dismutase) (Ji et al. 2004). This is suggested as the underlying mechanism for 
adaptation to training (Gomes-Cabrera, 2006). 
As shown by our results the possible effect of rhGH administration on genes related to 
immune function and regulation such as IL6 can be inhibited by NFκB, GZMA, PRF1, 
IL10R gene expression up-regulation. Even if the induction of mRNA is not always followed 
by an increase in the related protein expression or its activity, our results suggest that rhGH 
administration can possibly benefit athletes by up-regulating PRF1 mRNA as well as GZMA, 
IL10R, IL6R expression. 
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Miles and colleagues (2002) evaluated the perforin gene expression using quantitative RT–
PCR from moderately trained runners (males from 18 to 40 years old) and compared it to 
controls before exercise, immediately after (0h), 1.5, 5, and 24 h following a 60 minutes run 
at 80% of VO2 peak. The exercise bout decreased the PFR1 gene expression in the runners 
group from before to after exercise and this decrease was maintained over 24 h.  
4.4 Limitations of the study 
This study respected the initial healthy status of its sample limiting the time of rhGH 
administration to a short-term of 7 days, where although no side effects were reported it is not 
a comparable dose to the ones suggested by the literature to be a explicitly lower than the 
doses used by athletes. Nevertheless, the dose applied in our study revealed consistent 
changes in the aspects evaluated. 
It is noteworthy that the dose of rhGH administered was not based on the individual body 
weight or composition of subjects, being the same (1mg/day) for all the subjects, which could 
lead to different rhGH absorption due to different body composition. 
In summary, this study encompassing with thirty healthy young males demonstrated some of 
the effects of rhGH administration to a healthy population such as the acute change in the 
blood rheology through the increased RBC aggregation, as well as the late activation of Th 
lymphocytes in the release of anti-inflammatory interleukins and at the molecular level 
reporting the increased mRNA expression of selected genes.      
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Chapter 5 
Conclusions, Proposed Studies and Practical implications 
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5.1 Conclusion 
According to the World Anti Doping Code (WADA, 2009), there are three main reasons, for 
including a substance in the list of prohibited substances: medical or other scientific evidence, 
pharmacological effect or experience that the substance or method, alone or in combination 
with other substances has the potential to enhance or enhances sport performance, the 
substance represents an actual or potential health risk to the athlete and that the use of the 
substance violates the spirit of sport described in the Code. At least two of these reasons were 
shown in our study. 
As shown in this thesis, the short-term administration of rhGH lead to a negative effect on the 
blood circulation of a healthy population based on an increase in the native aggregation of 
erythrocytes defaulting the optimum flow of O2.  Based on the fact that GH is considered a 
major issue in the doping control among professional and amateur athletes, it is of crucial 
importance to report its effects on the blood rheology of healthy subjects. The observed 
increase in native aggregation is considered a determinant of the blood flow at low flow shear 
rates in the microcirculation possibly interfering with the regulation of O2 supply to the 
tissues.  
Furthermore, it is conclusive that short-term administration of rhGH can increase the 
expression of genes with anti-inflammatory action in PBMC of healthy young males 
suggesting a link between rhGH and molecular regulation of immune function in healthy 
population. It is portentous that rhGH may act on CD4+T lymphocytes by increasing IL10 
production and may then be a key component in T cell activation as the values of IL10 in 
athletes was previously reported to be lower than the healthy subjects’ values (Dorofeyeva 
and Dorofeyev, 2004).  
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Additionally, immune function and cytokine production, as assessed by CD4+ Th1 and Th2 
cytokines, showed a chronic effect of rhGH to specific anti-inflammatory cytokine release, a 
possible advantage for the adjustment of the athletes’ immunological status and consequently 
sports performance. 
The results of this study demonstrated at the molecular level the effects of the short-term 
administration of rhGH in the up regulation of the anti inflammatory IL10 gene pathway 
through the up regulation of IL10R. This suggests that the gene expression evaluation might 
be a sensitive way of investigating traces of the use of rhGH.  
5.2 Proposed studies 
Longer rhGH administration protocols may provide different results from the ones presented 
in this thesis as the acute effects on native aggregation noticed on Day 8. It suggests the 
possibility of extended increased aggregation and consequently decreased erythrocytes flow.  
Perhaps longer duration of rhGH administration could generate a chronic GH negative 
feedback effect on its own secretion, predominantly through increased hypothalamic 
somatostatin secretion and may be important in the physiological control of pulsatile GH 
secretion. 
The use of different doses of rhGH may affect in different ways the parameters evaluated in 
the three studies presented in this thesis. Blood viscosity was not evaluated in Study One but 
it could have been an important indicator of the detrimental effects of the increased native 
aggregation presented in this study.  
Future studies should examine the effects of rhGH in the top level athletes since it is well 
shown by the literature that athletes present a very particular immune function with high level 
of inflammation reported. Whether rhGH can be an advantage for the immune function of 
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this population, it is to be studied. Further research should be undertaken to assess the role of 
IL10 expression following rhGH biological pathway.  
The B lymphocyte numbers and percentage, expression of CD19, remained unaltered 
throughout the study in both groups and the B lymphocyte activity was not evaluated. This 
should be evaluated in future studies since preciously Yoshida (1992) showed they have a 
direct stimulating effect on B lymphocytes.  
Further investigation should evaluate important genes connected to Th lymphocytes  since it 
was shown in this thesis that Th cytokines production was effectively altered by rhGH 
administration. Important genes related to immune system such as Tyrosine kinase 2 encodes 
a member of the JAK protein families, which was shown to be the pathway of action of GH. 
Cytotoxic T-lymphocyte-associated protein 4 (CTLA4), is a member of the immunoglobulin 
superfamily and encodes a protein which transmits an inhibitory signal to T cells.  CTLA4 
inhibits T lymphocyte activation by reducing IL2 release and expression, and by arresting T 
cells at the G1 phase of the cell cycle which is the interval between mitosis and DNA 
replication being characterized by cell growth (Appleman, 2000). Chemokine (C-X-C motif) 
receptor 3, this gene is prominently expressed in in vitro cultured effector/memory T cells, 
and in T cells present in many types of inflamed tissues. It is suggested that this gene and its 
cytokines participate in the recruitment of inflammatory cells. 
5.3 Practical implications 
The demonstrated effects of short-term administration of rhGH in a healthy population at the 
molecular level leads to a large margin of posterior consequences in the immune cells 
activation. This must be brought to the attention of coaches, athletes and sports professionals. 
This study provided evidence of the influence of rhGH on the immune system and on the 
regulation of mRNA expression of selected genes of healthy young males. Referred results 
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can lead to several outcomes since the evaluated variables of this study have a central role in 
the cascades of reactions in the immune function of the subjects and can be possibly applied 
to athletes.    
Additionally, it should be noted that the acute effects reported at the RBC aggregation could 
negatively interfere with the athletes’ performance in high O2 demand situations.       
In conclusion, the results discussed in this thesis show that there are beneficial effects of 
short-term administration of rhGH to healthy young males as it generates an anti-
inflammatory response in the function of lymphocytes and up-regulation in the mRNA 
expression of selected genes related to immune system. However, the acute response of red 
blood cell aggregation raises a concern and is a potential threat to athletes’ well being.   
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1 - Growth Hormone Study 
 
Strength Trained Subjects Required 
 
This research is investigating the effects of Growth Hormone on muscular strength and anti-
doping markers.  
 
To be eligible subjects need to be: 
 
• Healthy males between 18-35yrs 
• Been resistance training at least 2-3 times per week for the previous 12 months 
• Familiar with the bench press exercise.  
 
For more information contact: 
Sandra Ramos 0413 038 685 or 
Dr Shane Rogerson 0415 498 099 
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2 - SELECTION OF SUBJECTS/VOLUNTEERS 
 
CRITERIA TO BE USED 
 
Subject Inclusion criteria: 
 
1. Males aged 18-35 years 
 
2. Have not used any doping substance or performance enhancing supplements in the 
previous 6 months. This excludes protein powder.  
 
3. Body weight between 70-110 kg 
 
4. A minimum of 1 year weight training experience 
Have been training at least 3 times a week for the previous 12 months. 
Experience with performing Bench Press exercise.  
 
5. Australian citizen.  
 
6. Participants will have a urine test to determine use of banned substances ie a drug test 
(IOC/WADA). If found positive they will be removed from the study.  
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Subject Exclusion Criteria:  
 
1. Regular user of therapeutic and/or recreational drugs. 
 
2. Contraindications or risk to exercise (recent injuries/risk factors for maximal strength 
testing etc).  
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3 - Subject Inclusion/Exclusion Questionnaire 2008 
 
If you are unsure about any of the following questions please seek clarification before 
responding. 
 
 
SUBJECTS NAME (please print)  
 
DOB:  
 
Current Bodyweight  
 
1. In the last 12 months how many times per week do you resistance train?  
 
2. Are you familiar with the Bench Press exercise?  YES  NO 
 
3. Are you currently suffering from any chronic (long-term) injury that you feel may 
affect your ability to lift maximum loads during a bench press exercise or may affect 
your ability to maintain your training during the research period? Give details if 
relevant: 
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4. Are you prepared to maintain your current training throughout the research period (eg 
no changes to volume or intensity).  YES  NO 
 
5. Do you smoke?  YES  NO 
 
6. Have you used any performance enhancing drugs in the previous 12 months? 
 
YES  NO 
 
 
7. Do you use recreational drugs? YES  NO 
 
 
8. Are you currently taking any prescription medication? YES  NO 
 
 
9. Do you use any nutritional supplements?  YES  NO 
 
 
10. Are you an Australian citizen YES  NO 
 
I have provided a truthful 
response to all of these 
questions (signed): 
  
Date: 
 
Researcher       Date   
Introduction
Physical activity levels in the general community are low 
and decreasing (AIHW, 2004). The typical physical working 
capacity or ability to undertake prolonged moderate or 
vigorous exercise is poor. This is because in the absence 
of specific, dedicated exercise time, the majority of people 
in developed countries such as Australia are becoming 
increasingly sedentary at work and at home, have low 
energy expenditure in leisuretime pursuits and have low 
participation rates in active transport. 
It is not uncommon for some people to go for many 
months or even years without undertaking any planned 
or structured physical activity. When these people decide 
to alter lifestyle patterns, join a gym or begin regular 
physical activity they are often unsure about how to be 
active. Unfortunately, through inappropriate exercise 
prescription or knowledge of the principles of progressive 
overload, many people do too much too soon. The 
result may be extreme muscle soreness or joint problems, 
or in rare cases they may place themselves at higher risk 
for acute cardiovascular problems. For many people 
this is a demotivator and is related to the high dropout 
rates typically found for these new programs.  
Who is it for?
The Sports Medicine Australia (SMA) pre-exercise 
screening system is a tool for exercise professionals 
to use when deciding if a person is at a high risk for 
these problems and is therefore recommended for 
medical clearance before embarking on an exercise 
program. Also, the screening system helps to identify 
those at low or moderate levels of risk during exercise 
and directs them to begin a tailored physical activity 
program without the need to seek medical clearance. 
This is the most common route for the majority of the 
population. Undertaking regular physical activity is 
important for the health of everyone. 
The SMA screening system is part of the broader 
effort to encourage physical activity. It is designed 
to provide a level of guidance so that those who are 
beginning regular physical activity are directed in an 
appropriate way to increase their safety and help them 
enjoy the experience.  The SMA pre-exercise screening 
system is a modification of the American College of 
Sports Medicine’s (ACSM) guidelines for pre-exercise 
screening and testing (ACSM, 2000). The ACSM 
guidelines are recognised as an important benchmark 
for the following reasons (Olds and Norton, 1999): 
• The ACSM is an internationally recognised leader in 
the areas of exercise science and sports medicine
• The ACSM has produced six editions of their 
guidelines for pre-exercise screening and testing 
over the past 30 years which have been based 
on several decades of scientific, clinical and 
epidemiological research 
• Similarities between Australian and North American 
populations in areas such as physical activity 
patterns, and morbidity and mortality statistics in 
lifestyle diseases such as cardiovascular disease, 
diabetes and cancer, justify their adaptation for use 
in Australia. 
Sports Medicine Australia (SMA) 
pre-exercise screening system 2005
Disclaimer: The Sports Medicine Australia pre-exercise 
screening system 2005 (“screening system”) has been 
established by Sports Medicine Australia and is designed 
to filter out people at high risk for certain exercise related 
complications. However, the screening system neither 
purposes nor is intended or implied to be advice on 
a particular matter or a substitute for advice from an 
appropriately qualified medical professional, and no 
express or implied warranty of safety should result from 
a person using or complying with the screening system.  
Participants and exercise professionals taking part in, or 
conducting exercise programs assume all inherent risks of 
any exercise program and the screening system in no way 
guarantees against injury or death. No responsibility or 
liability whatsoever can be accepted by Sports Medicine 
Australia for any loss, damage or injury that may arise 
from any person acting on any statement or information 
contained in these guidelines.
SMA pre-exercise screening  
system  
1) The first stage of the screening system is a filter to 
screen out those people who are at a high risk level 
for exercise-related complications due to underlying 
cardiovascular, cerebrovascular, respiratory or 
metabolic diseases. These are people with known 
disease or who have signs and/or symptoms of 
disease. Other serious or potentially serious medical 
conditions that may be exacerbated during exercise 
are also important at this stage (see notes at ‘Stage 
1 - Overview’ flow chart). It is recommended that this 
relatively small group of ‘high risk’ clients seek medical 
clearance before beginning an exercise program or 
undertaking aerobic fitness testing. 
The questionnaire shown below is the tool used to 
identify who is at high risk at this stage.  
• If a person answers ‘Yes’ to any of these questions 
then they are considered to be in the ‘high risk’ 
group. There is, however, scope for the exercise 
specialist to use a level of professional judgement 
when interpreting these responses. For example, 
swelling or fluid accumulation about the ankles 
may be related to local joint problems or recent air 
travel rather than, for example, due to underlying 
cardiovascular pathology. For those with well 
controlled diabetes or stable cardiovascular 
conditions (coronary heart disease (CHD), cardiac 
failure, stroke and peripheral vascular disease 
(PVD)) there is generally no need to seek medical 
clearance before beginning a low - moderate 
physical activity program such as regular walking 
(NHF 2005). Also, ‘other’ medical conditions that 
may be mentioned are essentially endless so there 
requires a level of interpretation in deciding if the risk 
of adverse effects outweighs the known benefits of 
individually-tailored regular physical activity. 
Those who are NOT at high risk can begin low or 
moderate level physical activity without the need 
for medical clearance (see details below for specific 
guidelines and rare exceptions). These people may 
also proceed to stage 2 of the screening system if there 
is a desire to exercise at vigorous intensity levels or 
if there is an intention to undergo exercise testing to 
maximal levels.  
2)  The second stage of the screening system is used 
to determine those people who are categorised as 
moderate or low risk for exercise-related complications 
due to underlying cardiovascular, cerebrovascular, 
respiratory or metabolic diseases (or other medical 
conditions referred to below).  
Stage 2 identifies those at moderate risk who are 
either ‘older’ and/or who have 2 or more risk factors 
for heart disease. For these clients they are classified 
as moderate risk and can undertake physical activity 
up to moderate intensity levels (for example, walking 
for the majority of people), without medical clearance. 
Stage 2 procedures and measures can also be used 
as a valuable adjunct in the general health appraisal of 
clients and to monitor changes in risk factor status over 
time and with lifestyle changes.
Those who are ‘younger’ and who have less than 2 
risk factors are considered low risk for exercise-related 
complications. They can also be tested to maximal 
levels without medical clearance or supervision. 
The general process for administering the pre-exercise 
screening system is illustrated below. Specific flow 
charts [decision-making trees] are then presented for 
each of the two stages.
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STAGE 1 Administer the SMA pre - exe rcise screening questionnaire to new clients or those 
significantly upgrading their exe rcise ac t i v i ty to determine who is at a h i g h r i s k
High risk clients should get medical clearance befo re
beginning an exe rcise pro g ram or undergoing exe rcise testing
Others can begin a low - moderate intensity physical ac t i v i ty pro g ram without
the need for medical cleara n c e* . For those people interested in commencing a
v i g o rous intensity ac t i v i ty pro g ram or wanting to undergo exe rcise testing to
maximal levels then proceed to stage 2
* see details below for specific guidelines and ra re exc e p t i o n s
1B
1C
1A
administer QUESTIONNAIRE
STAGE 2 Use the (a) age categories and (b) card i ovascular risk factors to decide who is 
at a m o d e rat e or l ow l evel of risk
2A
2B
2C
is the client 
‡ 4 5 yr (if male) 
or 
‡ 55 yr (if fe m a l e ) ?
If YES then they are at a
m o d e rate risk for CHD
Younger clients with
less than 2 card i ac
risk factors are at l ow
r i s k for CHD
If the client is in the
‘older’ cat e g o ry OR
if the client has 2
or more card i ac risk
factors THEN they
a re at a m o d e rat e
r i s k for CHD
Check for RISK FA C T O R S
P re - exe rc ise sc reening sys tem 2005
Spo r t s  Med ic ine  Aus t r a l i a  ( SMA)  -  S t age  1  ov e r v i ew
( k n own d i sea se s  o r  s i gns  and  symptoms  o f  med i ca l  cond i t ions )
known 
disease ?
new client
administer the
questionnaire 
one or more
signs or
symptoms ?
(1) Medical clearance is NOT necessary to begin a low-moderate intensity physical
activity program
(2) Medical clearance is NOT necessary to undertake a low-moderate intensity
submaximal fitness test
(3) These people are encouraged to regularly undertake low-moderate levels* of
physical activity.
NOTES:  
# Some of these conditions might include a history of blood clotting, osteoporosis, bone fractures or serious musculoskeletal disorders, or if they have
recently lost a large amount of body mass without trying to. Other types of conditions might include psychiatric disorders, later-stage pregnancy or those
with a history of health problems during pregnancy. Those people taking medication(s) for medical conditions listed may also need medical clearance.
* low intensity physical activity is defined as activity eliciting a HR of < 55% HRmaximum or rating of perceived exertion [RPE] up to 11 on Borg’s 20-point
scale [2 on the 10-point scale]
moderate intensity physical activity is defined as activity eliciting a HR of ³ 55% and < 75% HRmaximum or REP up to 13 [3 on the 10-point scale]
vigorous intensity physical activity is defined as activity eliciting a HR of ³ 75% HRmaximum or RPE of 14 or above [5 on the 10-point scale]
Stage 1
Does the client have known
cardiovascular,
cerebrovascular, respiratory
or metabolic disease, or is
there any other condition
you think requires medical
opinion# ?
OR
Does the client show one
or more signs or symptoms
of major cardiovascular,
cerebrovascular, respiratory
or metabolic disease ?
No
No
• client DOES need medical clearance before
beginning an exercise program or undertaking
aerobic fitness testing
Yes
Yes
N a m e A g e Gender   M   F
A d d r e s s P h o n e D a t e
1 Have you ever had a heart attack, coronary revascularisation surgery or a stroke ? N o Ye s
2 Has your doctor ever told you that you have heart trouble or vascular disease ? N o Ye s
3 Has your doctor ever told you that you have a heart murmur ? N o Ye s
4 Do you ever suffer from pains in your chest, especially with exercise ? N o Ye s
5 Do you ever get pains in your calves, buttocks or at the back of your legs 
during exercise which are not due to soreness or stiffness ? N o Ye s
6 Do you ever feel faint or have spells of severe dizziness, particularly with exercise ? N o Ye s
7 Do you experience swelling or accumulation of fluid about the ankles ? N o Ye s
8 Do you ever get the feeling that your heart is suddenly beating faster, racing or  
skipping beats, either at rest or during exercise ? N o Ye s
9 Do you have chronic obstructive pulmonary disease, interstitial lung disease,
or cystic fibrosis? N o Ye s
1 0 Have you ever had an a t t a c k of shortness of breath that developed when you 
were not doing anything strenuous, at any time in the last 12 months ? N o Ye s
1 1 Have you ever had an a t t a c k of shortness of breath that developed after you 
stopped exercising, at any time in the last 12 months ? N o Ye s
1 2 Have you ever been woken at night by an a t t a c k of shortness of breath, at any 
time in the last 12 months ? N o Ye s
1 3 Do you have diabetes [IDDM or NIDDM] ?
If so, do you have trouble controlling your diabetes? N o Ye s
1 4 Do you have any ulcerated wounds or cuts on your feet that do not seem to heal? N o Ye s
1 5 Do you have any liver, kidney or thyroid disorders? N o Ye s
1 6 Do you experience unusual fatigue or shortness of breath with usual activities? N o Ye s
1 7 Is there any other physical reason or medical condition, or are you taking any 
medication(s) which could prevent you from undertaking an exercise program, or
that you are concerned about? # N o Ye s
P re - exe rc i se  sc reen ing  sys tem 2005
Spo r t s  Med ic ine  Aus t r a l i a  ( SMA)  -  S t age  1 ques t ionna i re
NOTES:
# Some of these conditions might include a history of blood clotting, osteoporosis, bone fractures or serious musculoskeletal disorders, or if they
have recently lost a large amount of body mass without trying to. Other types of conditions might include psychiatric disorders, later-stage pregnancy
or those with a history of health problems during pregnancy. Those people taking medication(s) for medical conditions listed may also need medical
clearance.
Also, if any one or more of the risk factors [below] are extreme then the health and fitness professional should use professional judgement as to
whether medical clearance may be required.
is client ³ 4 5 y r
(male) or 
³ 55 yr  
( f e m a l e ) ?
from Stage 1
2 or more risk
f a c t o r s ?
Stage 2
[A] 
Is the client ³ 45yr (if a
male) or ³ 55 yr  (if a
female) ?
OR
[B]
Does the client have 2 or
more risk factors ? 
• client does NOT need medical clearance before undertaking an exercise program even up to vigorous intensity levels
• This group of younger, apparently healthy people are at lowest risk for cardiovascular events during vigorous intensity physical activity. For the
vast majority of these clients aerobic fitness testing to maximal levels may be conducted without extreme levels of risk. However, the health / fitness
professional needs to make a judgement based on the individual circumstances of risk versus benefit.
No
No
• client does NOT need medical clearance
before beginning a low - moderate intensity
exercise program
• client can undertake low - moderate intensity
submaximal aerobic fitness testing
• client DOES need medical clearance before
beginning a vigorous exercise program or
undertaking aerobic fitness testing to vigorous-
intensity levels
Yes
Yes
L O W   R I S K
P re - exe r c ise sc reening system 2005
Spo r t s  Med ic ine  Aus t r a l i a  ( SMA)  -  S t age  2  ov e r v i ew
( age  and r i s k  f a c t o r s )
P re - exe rc i se  sc reen ing sys tem 2005
Spo r t s  Med ic ine  Aus t r a l i a  ( SMA)  -  S t age  2  p r o c e d u res  
smoker ?
family history of
cardiovascular disease
family history of
cardiovascular disease
fasting glucose ³ 6.1
mmol.L–1
fasting glucose ³ 6.1
mmol.L–1
SBP ³ 140 or DBP ³ 90
mmHg
SBP ³ 140 or DBP ³ 90
mmHg
cholesterol > 5.2
or HDL < 0.9
sedentary lifestylecholesterol > 5.2
or HDL < 0.9
BMI ³ 30 or waist girth  >
100 cm
sedentary lifestyle
Is the client ³ 45 yr (if a male) or ³ 55 yr  (if a female) ?
No
No
No
No
No
No
NoNo
No No
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Stage 2 [B]
Does the client smoke cigarettes‡
regularly 
OR
have they quit smoking in the last 6
months ?
Does the client have a 1st ° male
relative [father, son, brother] or female
relative [mother, sister, daughter] who
has had a myocardial infarction,
coronary revascularisation, or died
suddenly due to a heart attack before
the age of 55 yr [males] or 65 yr
[females]?
Does the client have impaired fasting
glucose?
[fasting glucose ³ 6.1 mmol.L–1 on 2
separate occasions].
Does the client have systolic blood
pressure measured at  ³ 140 mmHg
on two separate occasions
OR
diastolic blood pressure measured at 
³ 90 mmHg on two separate
occasions
OR 
are they on antihypertensive drugs?
Does the client have a total serum
cholesterol concentration of > 5.2
mmol.L–1 or HDL < 0.9
mmol.L–1 or on lipid-lowering
medication
Does the client have an occupation
where they are seated for long periods
AND they do no regular exercise 
OR 
the client does not meet current PA
guidelines of 150 min of moderate PA
per week [Use AA questionnaire].
Is the client obese? [BMI ³ 30] 
OR 
do they have a waist girth 
> 100 cm?
If your client has
HDL cholesterol  >
1.6 mmol.L-1 then
take one risk factor
away from the total.
If they still have ³ 2
risk factors they
have ‘cardiac risk
factors’ and are in
the MODERATE RISK
group.
• client does NOT
need medical
clearance before
beginning a low -
moderate intensity
exercise program
• client can
undertake low -
moderate intensity
submaximal
aerobic fitness
testing
Your client is in a
MODERATE RISK
group due to their
age.
• client does NOT
need medical
clearance before
beginning a low -
moderate intensity
exercise program
• client can
undertake low -
moderate intensity
submaximal
aerobic fitness
testing
Notes: 
‡ includes all forms of smoking
such as pipes, roll-your-own and
c a n n a b i s
Stage 2 [A] 
Is your client in the ‘older’ age
category?
• client does NOT need medical clearance before undertaking an exercise program even up to vigorous intensity
levels.
• This group of younger, apparently healthy people are at lowest risk for cardiovascular events during vigorous intensity
physical activity. For the vast majority of these clients aerobic fitness testing to maximal levels may be conducted without
extreme levels of risk. However, the health / fitness professional needs to make a judgement based on the individual
circumstances of risk versus benefit.
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5 - Explanatory Statement 
 
Project Title:  Transcriptional regulation of gene expression in human lymphocytes: Potential 
application to the detection of recombinant human Growth Hormone (rhGH): A one-
year pilot project (Project Number: RO597) 
 
You are invited to participate in a study of the effects of Growth Hormone on the changes in 
gene expression within human white blood cells. 
 
We hope to develop a test to detect the use of the banned substance, human recombinant 
Growth Hormone (rhGH) in athletes. This initial “pilot” project has been funded by the Anti-
Doping Research Panel from the Commonwealth Department of Communication, 
Information Technology & the Arts. This project will investigate the effects of multiple doses 
(one dose per day for 7 days) of rhGH.  
 
You were selected as a possible participant in this study because you are a resistance-trained 
male aged 18-35 years of age, NOT currently involved in competition. 
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If you decide to participate, you will be asked to visit the University to undertake 
familiarisation and initial screening where a medical history, height, and weight will be 
recorded. If you are admitted to the study you will be randomly allocated to one of two 
groups: 
 
• Control (Placebo injection) 
• Experimental Group – one injection of rhGH a day for 7 days. 
 
At the commencement of the study, all subjects will have their 1RM (repetition maximum) 
for bench-press measured. Subsequently subjects will receive injections of either rhGH 
(Experimental Group) or Placebo (Control Group), according to the appropriate schedule. (as 
below) 
 
• Control Group: (Injection of Placebo) 
• Experimental Group: Daily injection of rhGH (1.0 mg) for seven (7) days, with 
collection of blood samples* on Days 0,1,8,15,22 & 29 
 
All injections will be administered by a qualified and experienced medical practitioner, who 
will monitor subjects throughout the study.  
 
*Note that blood sampling will involve venipuncture of a forearm vein and collection of 5-
10mL of whole blood. 
 
Subjects may experience some brief discomfort as the injection is administered. Possible 
adverse effects from administration of rhGH include oedema, muscle/skeleton/joint stiffness 
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or pain, or some sensory changes. Additional literature is available for subjects should they 
request any further information regarding the possible side-effects of rhGH. All subjects will 
be monitored by, and will have full access (24/7) to, the medical practitioner throughout the 
study. Participation of subjects in the study may be withdrawn should any adverse symptoms 
become apparent.  
 
 
If you have any queries or would like to be informed of the aggregate research finding, please 
contact either: 
 
Dr Bon Gray or;   
 
Dr Shane Rogerson. 
 
Faculty of Health Sciences & Medicine 
Bond University – Gold Coast. 
Queensland 4229. 
Ph: 07 5595 4400 (SR) or 07 5595 4454 (BG) 
Fx: 07 5595 4122. 
Email: srogerson@bond.edu.au or bgray@bond.edu.au 
 
 
Should you have any complaint concerning the manner in which this research is conducted, please do not 
hesitate to contact Bond University Research Ethics Committee, quoting the Project Number (above): 
 
The Complaints Officer 
Bond University Human Research Ethics Committee 
Bond University Research and Consultancy Services 
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Level 2, Central Building  
Bond University, QLD 4229. 
Telephone (07) 5595 4194 Fax (07) 5595 1120 
Email: buhrec@bond.edu.au  
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6- Participant Informed Consent 
 
I agree to take part in the above Bond University research project.  I have read the above 
Explanatory Statement and have been advised of any risks.  
 
 
I agree to receive injections of either rhGH or Placebo and provide blood samples as 
outlined above. 
 
 
______ Please tick here to acknowledge that you understand and agree to the above 
procedures. 
 
 I understand that any information I provide is confidential, and that no information that could 
lead to the identification of any individual will be disclosed in any reports on the project, or 
to any other party. 
 
I also understand that my participation is voluntary, that I can choose not to participate in part 
or all of the project, and that I can withdraw freely at any stage of the project. 
 
Please tick the appropriate box 
 
q The information I provide can be used by other researchers as long as my name and 
contact information is removed before it is given to them. 
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q The information I provide cannot be used by other researchers without asking me first. 
 
q The information I provide cannot be used except for this project 
 
 
Name: ...........................................................................................  (please print) 
 
 
Signature:  .........................................................................................................   
 
Date: ............................. 
 
Address:.............................................................................................................. 
 
............................................................................................................................ 
 
Phone Contact: ………………………………………………………….. 
 
Email Contact: ……………………………………………………………. 
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